<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="review-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Paediatr Drugs</journal-id><journal-id journal-id-type="iso-abbrev">Paediatr Drugs</journal-id><journal-title-group><journal-title>Paediatric Drugs</journal-title></journal-title-group><issn pub-type="ppub">1174-5878</issn><issn pub-type="epub">1179-2019</issn><publisher><publisher-name>Springer International Publishing</publisher-name><publisher-loc>Cham</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">26072040</article-id><article-id pub-id-type="pmc">4744260</article-id><article-id pub-id-type="publisher-id">137</article-id><article-id pub-id-type="doi">10.1007/s40272-015-0137-1</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title>Psoriasis in Children and Adolescents: Diagnosis, Management and Comorbidities</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Bronckers</surname><given-names>I. M. G. J.</given-names></name><address><phone>00 31 24 366 8235</phone><email>inge.bronckers@radboudumc.nl</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Paller</surname><given-names>A. S.</given-names></name><xref ref-type="aff" rid="Aff2"/></contrib><contrib contrib-type="author"><name><surname>van Geel</surname><given-names>M. J.</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>van de Kerkhof</surname><given-names>P. C. M.</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Seyger</surname><given-names>M. M. B.</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><aff id="Aff1"><label/>Department of Dermatology, Radboud University Medical Center, Ren&#x000e9; Descartesdreef 1, PO Box 9101, 6500 HB Nijmegen, The Netherlands </aff><aff id="Aff2"><label/>Department of Dermatology and Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, IL USA </aff></contrib-group><pub-date pub-type="epub"><day>14</day><month>6</month><year>2015</year></pub-date><pub-date pub-type="pmc-release"><day>14</day><month>6</month><year>2015</year></pub-date><pub-date pub-type="ppub"><year>2015</year></pub-date><volume>17</volume><fpage>373</fpage><lpage>384</lpage><permissions><copyright-statement>&#x000a9; The Author(s) 2015</copyright-statement><license license-type="OpenAccess"><license-p>
<bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.</license-p></license></permissions><abstract id="Abs1"><p>Psoriasis is a common chronic immune-mediated inflammatory skin disorder and begins in childhood in almost one-third of the cases. Although children present with the same clinical subtypes of psoriasis seen in adults, lesions may differ in distribution and morphology, and their clinical symptoms at presentation may vary from those reported by adult patients. Nevertheless, diagnosis of psoriasis is primarily based on clinical features. Pediatric psoriasis can have a profound long-term impact on the psychological health of affected children. Additionally, pediatric psoriasis has been associated with certain comorbidities, such as obesity, hypertension, hyperlipidemia, diabetes mellitus and rheumatoid arthritis, making early diagnosis and management essential. As guidelines are lacking and most (systemic) treatments are not approved for use in children, treatment of pediatric psoriasis remains a challenge. A prospective, multicenter, international registry is needed to evaluate these treatments in a standardized manner and ultimately to develop international guidelines on pediatric psoriasis. This article reviews current concepts in pediatric psoriasis including epidemiology, clinical features, diagnosis, the role of topical and systemic agents and the association with other morbidities in childhood.</p></abstract><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Springer International Publishing Switzerland 2015</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="d30e219"><title>Key Points</title><p><table-wrap id="Taba"><table frame="hsides" rules="groups"><tbody><tr><td align="left">In pediatric psoriasis patients, lesions may differ in distribution and morphology, and their clinical symptoms at presentation may vary from those reported by adults.</td></tr><tr><td align="left">There are currently no international standardized guidelines for medical treatment of pediatric psoriasis. Treatment is primarily based on published case series, guidelines for adult psoriasis, expert opinions and experience with these drugs in other pediatric disorders.</td></tr><tr><td align="left">Pediatric psoriasis has a high impact on the quality of life of those affected.</td></tr><tr><td align="left">There is increasing evidence suggesting an association of pediatric psoriasis with certain other morbidities, including hyperlipidemia, obesity, hypertension, diabetes mellitus and rheumatoid arthritis.</td></tr></tbody></table></table-wrap></p></sec><sec id="Sec1"><title>Introduction</title><p>Psoriasis is a common chronic immune-mediated inflammatory disorder affecting the skin, nails and joints in both children and adults. The skin disorder is estimated to affect 2.0&#x02013;3.5&#x000a0;% of the global population [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>]. A recent publication by Parisi et al. reported even higher percentages, with ranges up to 8.5&#x000a0;% depending on the studied population [<xref ref-type="bibr" rid="CR3">3</xref>]. Psoriasis begins in childhood in almost one-third of the cases [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR5">5</xref>], and the published incidence rates in children have more than doubled since 1970 [<xref ref-type="bibr" rid="CR6">6</xref>]. Psoriatic skin lesions are characterized by well defined erythematous scaly plaques, and tend to have a chronic relapsing and remitting course. Severity ranges from a few scattered plaques to involvement of almost the entire body surface. Psoriasis in children and adolescents can have a significant impact on quality of life by interfering with self-esteem, family and social relationships and school and work [<xref ref-type="bibr" rid="CR7">7</xref>&#x02013;<xref ref-type="bibr" rid="CR9">9</xref>]. Children suffering from psoriasis also have a higher prevalence of comorbidities, including obesity, diabetes mellitus, hypertension, rheumatoid arthritis, Crohn&#x02019;s disease and psychiatric disorders, compared with children without psoriasis [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR10">10</xref>&#x02013;<xref ref-type="bibr" rid="CR12">12</xref>]. Because of the burden of disease and the associated comorbidities, early diagnosis and management in children are essential.</p></sec><sec id="Sec2"><title>Epidemiology</title><p>Prevalence rates vary slightly, depending on age, gender, geographical location, definition of prevalence, study design and case definition. Clinical presentation and psoriasis severity may also contribute to variation in prevalence and incidence numbers [<xref ref-type="bibr" rid="CR3">3</xref>]. Although pediatric psoriasis is not uncommon, limited epidemiology data are available to date. It is estimated that approximately 30&#x02013;50&#x000a0;% of adults with psoriasis developed psoriasis before 20&#x000a0;years of age [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR14">14</xref>]. Gelfand et al. found that the prevalence of psoriasis in childhood in the UK was about 0.55&#x000a0;% in children aged 0&#x02013;9&#x000a0;years and 1.37&#x000a0;% in children aged 10&#x02013;19&#x000a0;years [<xref ref-type="bibr" rid="CR4">4</xref>]. This study also demonstrated that the prevalence increased more rapidly in females compared with males younger than 20&#x000a0;years. This finding is probably not due to females paying closer attention to their skin, but suggests an interaction between sex and the development of the psoriasis phenotype in young patients [<xref ref-type="bibr" rid="CR4">4</xref>]. Comparable prevalence results have been reported within the German (age 0&#x02013;9, 0.18&#x000a0;%; age 10&#x02013;19, 0.83&#x000a0;%) [<xref ref-type="bibr" rid="CR1">1</xref>] and Dutch populations (age 0&#x02013;10, 0.4&#x000a0;%; age 11&#x02013;19, 1.0&#x000a0;%) [<xref ref-type="bibr" rid="CR13">13</xref>]. In contrast to Europe, pediatric psoriasis was almost absent in an epidemiological study on childhood dermatoses performed in Asia [<xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR16">16</xref>]. This worldwide geographical variation seems to reflect the fact that psoriasis is a complex disease triggered by environmental factors in genetically susceptible subjects [<xref ref-type="bibr" rid="CR17">17</xref>].</p><p>The incidence of pediatric psoriasis has more than doubled between 1970 and 2000. A study by Tollefson et al. found the overall annual age- and sex-adjusted incidence of psoriasis to be 40.8 [95&#x000a0;% confidence interval (CI) 36.6&#x02013;45.1] per 100,000. An increase in triggering factors for psoriasis such as psychosocial stress, infections and being obese or overweight could be potential explanations for this development [<xref ref-type="bibr" rid="CR6">6</xref>]. Other exacerbating factors include trauma or irritation of the skin and the use of certain medications such as lithium, &#x003b2;-adrenergic antagonists and tumor necrosis factor alpha (TNF-&#x003b1;) inhibitors in children with Crohn&#x02019;s disease or juvenile idiopathic arthritis (JIA) [<xref ref-type="bibr" rid="CR18">18</xref>&#x02013;<xref ref-type="bibr" rid="CR20">20</xref>]. Most studies report no gender bias in pediatric psoriasis. Tollefson et al. described a female to male gender ratio of 1.10 [<xref ref-type="bibr" rid="CR6">6</xref>]. These findings were similar to other epidemiological studies from Australia, the USA, India and China [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR21">21</xref>&#x02013;<xref ref-type="bibr" rid="CR24">24</xref>]. However, a recent multicenter, cross-sectional study performed in 181 children with plaque psoriasis in the USA reported a female to male gender ratio of 1.48 [<xref ref-type="bibr" rid="CR25">25</xref>]. This female predominance was also demonstrated by others [<xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR27">27</xref>]. The mean age of onset varied from 8 to 11&#x000a0;years [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR28">28</xref>&#x02013;<xref ref-type="bibr" rid="CR30">30</xref>]. Interestingly, Augustin et al. demonstrated an almost linear increase in prevalence rates between 0 and 18&#x000a0;years rather than a &#x0201c;peak of onset&#x0201d; [<xref ref-type="bibr" rid="CR1">1</xref>].</p><p>About 30&#x000a0;% of individuals with psoriasis (children and adults) have an affected first-degree family member [<xref ref-type="bibr" rid="CR17">17</xref>].</p><p>The prevalence of psoriasis patients with an affected family member is observed to be greater in early-onset psoriasis (defined as psoriasis onset before the age of 16) than in adult-onset psoriasis (defined as psoriasis onset after the age of 16) [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR29">29</xref>, <xref ref-type="bibr" rid="CR31">31</xref>, <xref ref-type="bibr" rid="CR32">32</xref>]. Chiam et al. compared a Dutch and Singaporean group of children with psoriasis and reported that more Dutch children than Singaporean children had a first- or second-degree family member with psoriasis (73.3 vs. 13.6&#x000a0;%) [<xref ref-type="bibr" rid="CR26">26</xref>]. In an Australian population, 71&#x000a0;% of children with psoriasis had a first-degree relative with psoriasis. A positive family history of psoriasis was reported in 51.4&#x000a0;% of pediatric psoriasis patients in a multicenter, cross-sectional trial in the USA, with affected members being first-degree relatives in 59.8&#x000a0;% of those cases [<xref ref-type="bibr" rid="CR25">25</xref>]. These differences point to the role of genetic background within each population of patients with juvenile psoriasis [<xref ref-type="bibr" rid="CR23">23</xref>, <xref ref-type="bibr" rid="CR28">28</xref>].</p></sec><sec id="Sec3"><title>Clinical Features</title><p>Although children present with the same clinical subtypes of psoriasis seen in adults, lesions may differ in distribution and morphology, and their clinical symptoms at presentation may vary from those reported by adults. In childhood, typical erythematous plaques with overlying white scale are often thinner and smaller and psoriasis lesions tend to develop more often on the face and flexural areas. These lesions are characterized by maceration and less prominent scale [<xref ref-type="bibr" rid="CR22">22</xref>, <xref ref-type="bibr" rid="CR28">28</xref>]. Despite these predilection sites, psoriasis papules and plaques can develop on any skin area and are usually symmetrically distributed [<xref ref-type="bibr" rid="CR33">33</xref>]. Young children usually present with a diaper rash that is unresponsive to irritant diaper dermatitis treatment. Psoriatic diaper rash is seen in young infants and is characterized by sharply demarcated, minimally elevated erythematous plaques in the diaper area, involving the inguinal folds. The lesions are often macerated, and can develop into a widespread eruption within 1&#x02013;2&#x000a0;weeks [<xref ref-type="bibr" rid="CR32">32</xref>]. Morris et al. reported that 26&#x000a0;% of patients had a history of psoriasis diaper rash, but the diagnosis of true psoriasis in these infants remains controversial. Diaper psoriasis can be particularly difficult to treat [<xref ref-type="bibr" rid="CR23">23</xref>]. In older children, up to 75&#x000a0;% manifests with chronic plaque psoriasis [<xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR34">34</xref>]. This is the most common type of psoriasis in children and adults and is characterized by well defined erythematosquamous papules or plaques with overlying silvery-white scale. The lesions vary in size and develop primarily on the scalp, face and extensor surfaces of the elbow and knee. The scalp is the most frequently involved area and often the first site of presentation in children [<xref ref-type="bibr" rid="CR29">29</xref>, <xref ref-type="bibr" rid="CR35">35</xref>].</p><p>Guttate psoriasis is the second most common type of psoriasis in children [<xref ref-type="bibr" rid="CR21">21</xref>, <xref ref-type="bibr" rid="CR29">29</xref>]. Griffiths and Barker defined guttate psoriasis as an acute form of psoriasis in which papules erupt on the trunk approximately 2&#x000a0;weeks after a &#x003b2;-hemolytic streptococcal or viral infection [<xref ref-type="bibr" rid="CR17">17</xref>]. According to this definition, guttate psoriasis is self-limiting, resolving within 3&#x02013;4&#x000a0;months of onset [<xref ref-type="bibr" rid="CR17">17</xref>]. It has been reported that a proportion of individuals with guttate psoriasis eventually develop plaque psoriasis [<xref ref-type="bibr" rid="CR22">22</xref>, <xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR25">25</xref>, <xref ref-type="bibr" rid="CR36">36</xref>, <xref ref-type="bibr" rid="CR37">37</xref>]. Mercy et al. suggested that the risk of severe disease is higher if psoriasis started as guttate psoriasis which persisted [<xref ref-type="bibr" rid="CR25">25</xref>]. Prospective cohort studies are needed to further determine features and percentages of children with guttate psoriasis who develop plaque psoriasis.</p><p>Pustular psoriasis is seen in only 1.0&#x02013;5.4&#x000a0;% of children with psoriasis. In a minority of these patients, mutations of the interleukin-36 (IL-36) receptor antagonist (<italic>IL36RN</italic>) gene and subsequent upregulation of IL-1 production have been identified [<xref ref-type="bibr" rid="CR38">38</xref>]. Pustular psoriasis is characterized by localized or generalized superficial sterile pustules and can be accompanied by fever, malaise and arthralgias in the case of classical von Zumbusch type. Although pustular psoriasis is more common in adults, von Zumbusch pustular psoriasis and pustular psoriasis with an annular configuration occur more frequently in childhood [<xref ref-type="bibr" rid="CR31">31</xref>, <xref ref-type="bibr" rid="CR39">39</xref>].</p><p>Other less common subtypes of psoriasis are inverse psoriasis, palmoplantar psoriasis, isolated facial psoriasis, linear psoriasis and erythrodermic psoriasis [<xref ref-type="bibr" rid="CR17">17</xref>]. Erythrodermic psoriasis is characterized by erythema and scaling on more than 90&#x000a0;% of the body surface area. The condition is extremely rare in children and can be life-threatening because of severe hypothermia, hypoalbuminemia and cardiac failure [<xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR32">32</xref>].</p><p>Psoriasis of the skin can be accompanied by changes of the nail plate and nail bed. Nail changes have been reported in up to 40&#x000a0;% of children with psoriasis and more often in boys than in girls [<xref ref-type="bibr" rid="CR25">25</xref>, <xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR33">33</xref>]. Nail changes can precede, coincide with, or develop after skin psoriasis. Whether these changes relate to patient age or disease severity vary among studies [<xref ref-type="bibr" rid="CR25">25</xref>, <xref ref-type="bibr" rid="CR40">40</xref>]. The most common presentation is pitting of the nail plate. Other characteristics include oil spots, onycholysis (distal separation of the nail plate from the nail bed), subungual hyperkeratosis, onychodystrophy and splinter hemorrhages [<xref ref-type="bibr" rid="CR41">41</xref>]. Juvenile psoriatic arthritis (JPsA) is another manifestation of psoriasis in children. Because of difficulties in diagnosis and classification of psoriatic arthritis in children, prevalence data range from 1 to 10&#x000a0;% of children with psoriasis [<xref ref-type="bibr" rid="CR22">22</xref>, <xref ref-type="bibr" rid="CR25">25</xref>]. Approximately 7&#x000a0;% (range 0&#x02013;11&#x000a0;%) of all patients with JIA appear to have JPsA [<xref ref-type="bibr" rid="CR42">42</xref>&#x02013;<xref ref-type="bibr" rid="CR46">46</xref>]. JPsA is included under the term JIA. Following the introduction of the International League of Associations for Rheumatology (ILAR) criteria for JIA, JPsA has become a better recognized inflammatory arthritis in children. According to these criteria, JPsA can be diagnosed in the presence of skin psoriasis, or in the absence of a rash, if there are nail changes and/or a first-degree relative with psoriasis [<xref ref-type="bibr" rid="CR47">47</xref>]. Psoriatic arthritis is more common in adults, with prevalence data up to 30&#x000a0;% [<xref ref-type="bibr" rid="CR34">34</xref>, <xref ref-type="bibr" rid="CR48">48</xref>, <xref ref-type="bibr" rid="CR49">49</xref>]. The peak of onset in childhood is between ages 9 and 12, and the skin psoriasis often precedes psoriatic arthritis. Although a relationship between nail involvement and psoriatic arthritis in adults has been suggested, recent studies in both children and adults do not support this correlation [<xref ref-type="bibr" rid="CR25">25</xref>, <xref ref-type="bibr" rid="CR32">32</xref>, <xref ref-type="bibr" rid="CR50">50</xref>].</p></sec><sec id="Sec4"><title>Diagnosis</title><p>In addition to the clinical features described above, children often present with a thinner surface scale compared with adults. When scraping off scales, punctuate bleeding spots occur, a phenomenon known as the Auspitz sign. The occurrence of lesions in areas of trauma, also called isomorphic response or Koebner phenomenon, and residual pigmentation following healing of lesions are other typical diagnostic features of psoriasis [<xref ref-type="bibr" rid="CR34">34</xref>].</p><p>Although the diagnosis of psoriasis is primarily based on clinical features, biopsy can help to confirm the diagnosis in children with atypical presentations. Histological features of psoriasis include parakeratosis, loss of the granular cell layer, elongation of the rete ridges, neutrophilic aggregates within the epidermis (microabscesses of Munro), dilated blood vessels in the dermis, and perivascular lymphocytic infiltrates [<xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR51">51</xref>, <xref ref-type="bibr" rid="CR52">52</xref>]. These characteristics may vary depending on site of biopsy, psoriasis subtype, and whether children have been treated with topical and/or systemic treatments. Given that the diagnosis is usually made on the basis of morphology and distribution, a biopsy is virtually never performed, especially not in children. In atypical cases in which a diagnosis is required, topical therapy should ideally be discontinued prior to biopsy to avoid alteration of histological features [<xref ref-type="bibr" rid="CR53">53</xref>].</p><p>Dermoscopy has become a standard diagnostic tool in dermatology. Although this technique permits visualization of morphological structures invisible to the naked eye, it is not commonly used in the diagnosis of psoriasis. Lallas et al., however, suggested that dermoscopy could distinguish psoriasis from other common skin diseases such as dermatitis [<xref ref-type="bibr" rid="CR55">55</xref>]. Dotted vessels regularly distributed over a light red background and diffuse superficial white scales are typical dermatoscopic characteristics of a psoriasis plaque [<xref ref-type="bibr" rid="CR54">54</xref>, <xref ref-type="bibr" rid="CR55">55</xref>]. Further research is warranted to determine the added value of dermoscopy in diagnosis and predicting response to treatment.</p></sec><sec id="Sec5"><title>Management</title><p>Treating pediatric psoriasis can be challenging and requires careful compliance to a specific treatment regimen. Poor treatment adherence is rampant in psoriasis, in particular to topical agents [<xref ref-type="bibr" rid="CR56">56</xref>, <xref ref-type="bibr" rid="CR57">57</xref>]. Educating the patient and family on the chronicity of psoriasis, triggering factors, and treatment modalities is important, in addition to prescribing treatment. Timing of the first return visit may be a practical tool to enhance patient adherence [<xref ref-type="bibr" rid="CR29">29</xref>]. Return visits can induce &#x0201c;white coat compliance&#x0201d; in which the expectation of frequent monitoring can enhance patients&#x02019; use of medication [<xref ref-type="bibr" rid="CR58">58</xref>]. Psychosocial support is another important component of therapy for children with psoriasis [<xref ref-type="bibr" rid="CR7">7</xref>].</p><p>There are currently no international standardized guidelines for medical treatment of pediatric psoriasis. To date, treatment is primarily based on published case reports, guidelines for adult psoriasis, expert opinions and experience with these drugs in other pediatric disorders. The range of psoriasis treatments has been expanded during the past several years, and multiple topical agents, phototherapy and systemic and biological agents are available to date [<xref ref-type="bibr" rid="CR53">53</xref>]. Several factors need to be taken into account when selecting a specific treatment, e.g., age, quality of life, severity of psoriasis, location of psoriasis, type of psoriasis, tolerability, safety and patient preferences [<xref ref-type="bibr" rid="CR59">59</xref>&#x02013;<xref ref-type="bibr" rid="CR61">61</xref>].</p></sec><sec id="Sec6"><title>Topical Treatments</title><p>The majority of children with psoriasis can be managed with topical treatment, which is considered first-line therapy in psoriasis. However, most are not approved for pediatric use, requiring off-label prescribing [<xref ref-type="bibr" rid="CR61">61</xref>]. The most commonly used topical agents will be reviewed below. The vehicle for treatment is important and depends on the location of psoriasis, lesional characteristics, and patient preference [<xref ref-type="bibr" rid="CR62">62</xref>]. Available vehicles include creams, ointments, foams, gels and lotions.</p><sec id="Sec7"><title>Topical Corticosteroids</title><p>Topical steroids are the most commonly prescribed medications to treat psoriasis in all age groups. Steroids are available in a wide variety of strengths and vehicles. In adults, low- to mid-potency corticosteroids are used in facial, flexural and genital lesions, with use of high-potency corticosteroids in combination with penetration enhancers in areas of thick skin, such as the palms and the soles. In a systematic review on treatments in childhood psoriasis, three studies on the efficacy and safety of topical corticosteroids were reported [<xref ref-type="bibr" rid="CR63">63</xref>]. The total number of treated children in these three studies was 20, with a treatment period of 2&#x000a0;weeks. Based on these studies, it was concluded that halobetasol cream 0.05&#x000a0;% and clobetasol propionate emulsion 0.05&#x000a0;% are efficacious in pediatric plaque psoriasis. Reported side effects were relatively mild in the treatment period of 2&#x000a0;weeks, with burning sensation at the site of application or skin atrophy reported most frequently [<xref ref-type="bibr" rid="CR63">63</xref>&#x02013;<xref ref-type="bibr" rid="CR65">65</xref>]. Apart from these studies with the strongest steroids available, no reports on the efficacy and safety of topical corticosteroids in pediatric psoriasis were found. Potential side effects of (prolonged) use in adults are skin atrophy/striae, telangiectasias, acneiform dermatitis, tachyphylaxis, periorificial dermatitis, hypertrichosis and, less commonly, suppression of the hypothalamic&#x02013;pituitary&#x02013;adrenal axis. Therefore, corticosteroids should be used with caution through intermittent or rotational use to limit possible side effects [<xref ref-type="bibr" rid="CR29">29</xref>, <xref ref-type="bibr" rid="CR32">32</xref>].</p></sec><sec id="Sec8"><title>Vitamin D Analogs Alone and in Combination with Topical Corticosteroids</title><p>Studies with topically administered calcipotriol and calcitriol have shown efficacy in pediatric psoriasis patients with only mild side effects [<xref ref-type="bibr" rid="CR63">63</xref>]. Localized skin irritation and pruritus are the most common side effects, and use of these preparations is therefore avoided on areas with thinner skin, such as the face, genital and flexural areas [<xref ref-type="bibr" rid="CR53">53</xref>]. However, calcitriol ointment has been found to be less irritating than calcipotriol ointment if used in intertriginous psoriasis [<xref ref-type="bibr" rid="CR29">29</xref>, <xref ref-type="bibr" rid="CR62">62</xref>]. Systemic absorption of vitamin D and increasing calcium levels could theoretically occur, but are unlikely if used appropriately [<xref ref-type="bibr" rid="CR34">34</xref>]. Use of up to 45&#x000a0;g/m<sup>2</sup>/week in pediatric patients with psoriasis does not seem to influence calcium levels in children from 3 to 14&#x000a0;years [<xref ref-type="bibr" rid="CR66">66</xref>, <xref ref-type="bibr" rid="CR67">67</xref>]. Vitamin D analogs are not recommended in children under the age of 2&#x000a0;years [<xref ref-type="bibr" rid="CR62">62</xref>].</p><p>Although vitamin D analogs may be used as monotherapy, they are often prescribed in combination with topical corticosteroids, leading to drug synergy and a steroid-sparing effect [<xref ref-type="bibr" rid="CR32">32</xref>, <xref ref-type="bibr" rid="CR68">68</xref>]. In order to avoid separate applications and to enhance patient compliance, a commercially available compounded formulation containing calcipotriol and betamethasone dipropionate has been developed. Three studies describe the efficacy and safety of this formulation in pediatric psoriasis [<xref ref-type="bibr" rid="CR69">69</xref>&#x02013;<xref ref-type="bibr" rid="CR71">71</xref>]. In a prospective study with a clinical practice cohort, 73 children (aged 3&#x02013;18&#x000a0;years) with plaque type psoriasis were treated with calcipotriol/betamethasone dipropionate ointment once daily for 4&#x000a0;weeks and 4&#x000a0;days a week thereafter, with a median treatment duration of 35&#x000a0;weeks. The greatest effect of calcipotriol/betamethasone ointment was achieved within the first weeks. Continued treatment seemed to stabilize psoriasis in these children. Five children reported an adverse event, most commonly the development of striae [<xref ref-type="bibr" rid="CR69">69</xref>]. A multicenter, open-label study by Gooderham et al. found calcipotriol/betamethasone dipropionate gel applied once daily for 8&#x000a0;weeks in adolescents (aged 12&#x02013;17&#x000a0;years) with moderate to very severe plaque psoriasis to be well tolerated and effective. [<xref ref-type="bibr" rid="CR70">70</xref>]. Oostveen et al. demonstrated the effectiveness of calcipotriene/betamethasone dipropionate gel in pediatric scalp psoriasis (patient ages 4&#x02013;17&#x000a0;years) within the first 12&#x000a0;weeks of treatment (84 treatment episodes), with maintenance of this effect through the 48&#x000a0;weeks of follow-up. Striae of the skin (arms, trunk and legs) were described in three patients [<xref ref-type="bibr" rid="CR71">71</xref>].</p></sec><sec id="Sec9"><title>Calcineurin Inhibitors</title><p>In adults, tacrolimus (0.03 and 0.1&#x000a0;%) and pimecrolimus (1&#x000a0;%) have proven to be effective on psoriasis lesions on the face, genitalia and flexures and are a good alternative for psoriasis in these areas sensitive to the adverse effects of long-term topical steroid use [<xref ref-type="bibr" rid="CR72">72</xref>]. The efficacy and safety of tacrolimus 0.1&#x000a0;% applied twice daily in pediatric patients with psoriasis was evaluated in two nonrandomized clinical trials. All patients had cleared or improved substantially with the use of tacrolimus ointment within the first 30&#x000a0;days of treatment. The only reported adverse effect was pruritus in one patient [<xref ref-type="bibr" rid="CR73">73</xref>, <xref ref-type="bibr" rid="CR74">74</xref>]. There is currently not enough evidence for the use of pimecrolimus 1&#x000a0;% cream in the pediatric psoriasis population, as this was only described in two patients [<xref ref-type="bibr" rid="CR63">63</xref>]. Concomitant treatment with phototherapy and excessive sun exposure should be avoided because of the possible increased risk for skin cancer and lymphoma. However, further research is warranted to study possible long-term adverse effects [<xref ref-type="bibr" rid="CR60">60</xref>].</p></sec><sec id="Sec10"><title>Dithranol</title><p>Dithranol, also referred to as anthralin, is a topical agent with both anti-inflammatory and anti-proliferative properties and no significant systemic absorption. It is an effective and safe treatment option for pediatric psoriasis [<xref ref-type="bibr" rid="CR32">32</xref>, <xref ref-type="bibr" rid="CR36">36</xref>]. Short-contact dithranol at higher concentrations (0.1&#x02013;3&#x000a0;%) and applied for shorter periods of time (10&#x02013;30&#x000a0;min daily until irritation develops) maintains treatment efficacy but diminishes the risk of irritation and staining. Short-contact dithranol involves an intense treatment schedule and is preferably administered in a day care setting. In a retrospective study determining the position of dithranol in the treatment of pediatric psoriasis, a good or excellent result was achieved in 73.2&#x000a0;% of the patients. A median treatment period of 2&#x000a0;months was needed to achieve a median duration of remission of 5.5&#x000a0;months [<xref ref-type="bibr" rid="CR75">75</xref>]. Recently, Oostveen et al. demonstrated the efficacy and safety of short-contact dithranol therapy in a prospective observational study in 34 pediatric patients [<xref ref-type="bibr" rid="CR76">76</xref>]. A significant reduction in Psoriasis Area and Severity Index (PASI) score of 69.3&#x000a0;% was found, and the only reported adverse event was irritation of the skin. The efficacy and safety of short-contact dithranol treatment in day care with telemedicine (one visit per week and one scheduled video call via Skype) compares well to administration in a regular day care setting (two visits per week) [<xref ref-type="bibr" rid="CR76">76</xref>]. Although effective and safe to use in pediatric patients, dithranol can stain clothes and cause local skin irritation, particularly in facial, flexural, erythrodermic or pustular psoriasis [<xref ref-type="bibr" rid="CR34">34</xref>, <xref ref-type="bibr" rid="CR36">36</xref>].</p></sec><sec id="Sec11"><title>Phototherapy</title><p>Several studies have reported the use of phototherapy in pediatric psoriasis. Narrow band ultraviolet B light (nbUVB) seems to be an effective and well tolerated alternative treatment in pediatric patients with plaque and guttate psoriasis [<xref ref-type="bibr" rid="CR63">63</xref>, <xref ref-type="bibr" rid="CR77">77</xref>] that is poorly controlled with topical therapy. However, logistics and frequency of appointments could be an issue for some patients and their parents. In 2011, a retrospective study in pediatric psoriasis patients (range 2&#x02013;18&#x000a0;years) demonstrated complete clearance in 51&#x000a0;% and a good response (at least 75&#x000a0;% improvement) in 41&#x000a0;% of the children. Mean duration of treatment was 3.3&#x000a0;months [<xref ref-type="bibr" rid="CR78">78</xref>]. Only a small number of pediatric patients were treated with psoralen plus UVA radiation (PUVA), which is now rarely used in children because of long-term toxicity [<xref ref-type="bibr" rid="CR53">53</xref>, <xref ref-type="bibr" rid="CR79">79</xref>]. Short-term side effects of phototherapy include erythema, burning, pruritus and blistering. Anxiety can also be a significant problem in children [<xref ref-type="bibr" rid="CR80">80</xref>]. Although long-term side effects (e.g., carcinogenesis, photoaging) of nbUVB and PUVA have been seen in adults [<xref ref-type="bibr" rid="CR81">81</xref>], current evidence is heterogeneous and needs to be interpreted with caution [<xref ref-type="bibr" rid="CR82">82</xref>, <xref ref-type="bibr" rid="CR83">83</xref>]. There is a need for long-term follow-up in order to further clarify these associations, especially in the pediatric population [<xref ref-type="bibr" rid="CR63">63</xref>, <xref ref-type="bibr" rid="CR79">79</xref>].</p></sec></sec><sec id="Sec12"><title>Systemic Treatments and Biologics</title><p>In children with moderate to severe psoriasis recalcitrant to topical treatment, systemic treatments are indicated [<xref ref-type="bibr" rid="CR63">63</xref>]. However, the choice of agent remains a challenge because of the limited number of clinical trials and lack of guidelines in this age group [<xref ref-type="bibr" rid="CR84">84</xref>]. Most of the systemic treatments are not approved to use in children and are used off-label. Therefore, daily practice clinical decision making can be complicated and challenging. A systematic review on the efficacy and safety of all systemic treatments in pediatric psoriasis by van Geel et al. provided evidence-based recommendations for the use of these agents in the pediatric psoriasis population [<xref ref-type="bibr" rid="CR85">85</xref>].</p><sec id="Sec13"><title>Methotrexate</title><p>Methotrexate (MTX) has been approved for treatment of severe psoriasis in adults. However, in children, MTX is only approved for treatment of JIA, inflammatory bowel disease (IBD) and certain malignancies [<xref ref-type="bibr" rid="CR29">29</xref>, <xref ref-type="bibr" rid="CR86">86</xref>]. The use of MTX in pediatric psoriasis has also been studied [<xref ref-type="bibr" rid="CR85">85</xref>]. A recent analysis of a prospective registry demonstrated the safety and efficacy of oral and/or subcutaneous MTX in 25 children with plaque psoriasis [<xref ref-type="bibr" rid="CR87">87</xref>]. Based on the available evidence, MTX is considered to be the systemic treatment of choice in children with moderate to severe plaque psoriasis and its variants [<xref ref-type="bibr" rid="CR85">85</xref>, <xref ref-type="bibr" rid="CR87">87</xref>, <xref ref-type="bibr" rid="CR88">88</xref>]. MTX can be administrated either orally or subcutaneously [<xref ref-type="bibr" rid="CR89">89</xref>]. To date there is no consensus about MTX dosing regimen and treatment duration in pediatric psoriasis. As soon as therapeutic control is achieved, it is recommended to taper the dose to an effective but lower maintenance dose in order to reduce side effects [<xref ref-type="bibr" rid="CR86">86</xref>]. Folic acid is routinely administered to further reduce these side effects. However, optimal dose and timing of folic acid administration is still unclear [<xref ref-type="bibr" rid="CR84">84</xref>, <xref ref-type="bibr" rid="CR90">90</xref>, <xref ref-type="bibr" rid="CR91">91</xref>].</p><p>The most common side effects include nausea, vomiting, fatigue, stomatitis and abnormal liver function tests. Bone marrow suppression, pulmonary toxicity, infections and hepatotoxicity including liver fibrosis have been rarely reported in children [<xref ref-type="bibr" rid="CR60">60</xref>, <xref ref-type="bibr" rid="CR86">86</xref>, <xref ref-type="bibr" rid="CR87">87</xref>, <xref ref-type="bibr" rid="CR92">92</xref>]. Bone marrow suppression is potentially life-threatening, and generally occurs within the first months of treatment. Laboratory testing is done on a regular basis to monitor for these potential side effects. In addition, concomitant use of medications such as nonsteroidal anti-inflammatory drugs and trimethoprim/sulfamethoxazole needs to be avoided as these can interact with MTX and increase its potential toxicity [<xref ref-type="bibr" rid="CR29">29</xref>, <xref ref-type="bibr" rid="CR86">86</xref>]. Alcohol is also strongly discouraged during MTX use because of its hepatotoxicity [<xref ref-type="bibr" rid="CR92">92</xref>].</p></sec><sec id="Sec14"><title>Cyclosporine</title><p>Cyclosporine is an immunosuppressant drug approved for treatment of psoriasis in adults. It has a rapid onset of action (2&#x02013;4&#x000a0;weeks) and is therefore considered to be an ideal drug for controlling unstable disease in this population [<xref ref-type="bibr" rid="CR89">89</xref>, <xref ref-type="bibr" rid="CR93">93</xref>&#x02013;<xref ref-type="bibr" rid="CR95">95</xref>].</p><p>To date, the efficacy of cyclosporine in pediatric psoriasis remains unclear [<xref ref-type="bibr" rid="CR85">85</xref>]. Children may require higher doses than recommended in adults, because of differences in pharmacokinetics and the greater body surface area to weight ratio in children [<xref ref-type="bibr" rid="CR89">89</xref>, <xref ref-type="bibr" rid="CR94">94</xref>, <xref ref-type="bibr" rid="CR96">96</xref>]. Reported side effects include nephrotoxicity, hypertension, nausea and diarrhea. Because evidence in children is limited, the lowest possible dose and shortest treatment period should be used. Close monitoring of blood pressure and renal function is required [<xref ref-type="bibr" rid="CR86">86</xref>, <xref ref-type="bibr" rid="CR90">90</xref>]. The long-term risk of non-melanoma skin cancers has also been described. Concomitant phototherapy should be avoided to further reduce the risk of these malignancies [<xref ref-type="bibr" rid="CR29">29</xref>, <xref ref-type="bibr" rid="CR60">60</xref>].</p></sec><sec id="Sec15"><title>Retinoids</title><p>The efficacy and safety of retinoid treatment in pediatric psoriasis treatment has been shown primarily in pustular and erythrodermic psoriasis [<xref ref-type="bibr" rid="CR85">85</xref>]. Etretinate was previously used but is no longer commercially available, and it has been replaced by acitretin, its active metabolite. The use of acitretin has only been described in a few children with psoriasis [<xref ref-type="bibr" rid="CR97">97</xref>, <xref ref-type="bibr" rid="CR98">98</xref>]. Mucocutaneous side effects such as cheilitis, xerosis, epistaxis, skin fragility, hair loss and ocular toxicities have frequently been reported [<xref ref-type="bibr" rid="CR60">60</xref>, <xref ref-type="bibr" rid="CR85">85</xref>]. Laboratory follow-up is needed to monitor for elevated liver enzymes and triglycerides. In addition, prolonged retinoid use has been associated with diffuse idiopathic skeletal hyperostosis, premature epiphyseal closure (at high doses) and decreased bone mineral density [<xref ref-type="bibr" rid="CR29">29</xref>, <xref ref-type="bibr" rid="CR99">99</xref>]. Due to the teratogenicity of oral retinoids and concerns about delayed clearance, the use in adolescent girls should be considered carefully. Pregnancy must be avoided until at least 3&#x000a0;years after stopping therapy [<xref ref-type="bibr" rid="CR34">34</xref>, <xref ref-type="bibr" rid="CR36">36</xref>].</p></sec><sec id="Sec16"><title>Fumaric Acid Esters</title><p>Fumaric acid esters (FAE) have a broad range of immunomodulatory effects and are registered for the treatment of moderate-to-severe plaque psoriasis in adults in Germany [<xref ref-type="bibr" rid="CR90">90</xref>]. In adults, doses can be titrated to a maximum of 720&#x000a0;mg daily, depending on clinical response and tolerability [<xref ref-type="bibr" rid="CR84">84</xref>, <xref ref-type="bibr" rid="CR90">90</xref>, <xref ref-type="bibr" rid="CR100">100</xref>, <xref ref-type="bibr" rid="CR101">101</xref>]. Although data on pediatric use are limited, a retrospective case series of 14 children demonstrated complete clearance of psoriasis in 36&#x000a0;%, good improvement in 7&#x000a0;%, partial response in 21&#x000a0;% and non-response in 36&#x000a0;% of pediatric patients. The median duration of treatment was 10&#x000a0;months (range 1&#x02013;80&#x000a0;months). A starting dose of dimethylfumarate of 30&#x000a0;mg was given, and was increased to a maximum daily dosage of 720&#x000a0;mg on the basis of clinical response and tolerability [<xref ref-type="bibr" rid="CR100">100</xref>]. Reported side effects include flushing, gastrointestinal complaints, eosinophilia, transient shifts in leukocyte counts, and elevated hepatic transaminases. Mild proteinuria and increased serum creatinine levels may also occur [<xref ref-type="bibr" rid="CR100">100</xref>, <xref ref-type="bibr" rid="CR102">102</xref>&#x02013;<xref ref-type="bibr" rid="CR104">104</xref>]. Although evidence to date is limited, FAE can also be considered in pediatric psoriasis if MTX is ineffective or contraindicated [<xref ref-type="bibr" rid="CR85">85</xref>].</p></sec><sec id="Sec17"><title>Biologics</title><p>Biologics are relatively new pharmacological agents that target specific mediators of the inflammatory cascade in psoriasis, including TNF-&#x003b1; and IL-12/23. Biologics offer more favorable dosing regimens and require less frequent lab monitoring than conventional systemic therapies. International guidelines about the use of biologics in pediatric psoriasis are lacking [<xref ref-type="bibr" rid="CR89">89</xref>]. Moreover, biologics have been associated with complications in both children and adults, including opportunistic infections, reactivation of latent tuberculosis and malignancies, in particular lymphomas. Although these complications are rare, and primarily reported in patients with arthritis, IBD or sarcoidosis, the advantages must be balanced with some caution [<xref ref-type="bibr" rid="CR89">89</xref>, <xref ref-type="bibr" rid="CR106">106</xref>]. As long-term safety data are lacking, potential risks should be discussed with the patient and parents prior to decision making.</p><sec id="Sec18"><title>Etanercept</title><p>Although approved in Europe and Canada for children aged 8&#x000a0;years and older, the US Food and Drug Administration (FDA) has yet to approve psoriasis as an indication for etanercept in the pediatric population [<xref ref-type="bibr" rid="CR86">86</xref>, <xref ref-type="bibr" rid="CR89">89</xref>, <xref ref-type="bibr" rid="CR107">107</xref>]. In 2008, a double-blind, multicenter, phase III, randomized controlled trial evaluated the safety and efficacy of etanercept in children aged 4&#x02013;17 with moderate-to-severe plaque psoriasis. Etanercept was well tolerated and demonstrated a significantly reduced severity of disease at week 48 and 96. Most common short-term side effects included infections such as pharyngitis, bronchitis and gastroenteritis. No deaths, cancers, opportunistic infections, tuberculosis or demyelination events were reported [<xref ref-type="bibr" rid="CR105">105</xref>, <xref ref-type="bibr" rid="CR108">108</xref>]. Although long-term etanercept treatment seems well tolerated in children with JIA, the association between TNF blockers and development of malignancy remains unclear [<xref ref-type="bibr" rid="CR109">109</xref>, <xref ref-type="bibr" rid="CR110">110</xref>]. Therefore, etanercept is still considered to be a third-line drug in severe and/or recalcitrant psoriasis in children [<xref ref-type="bibr" rid="CR85">85</xref>, <xref ref-type="bibr" rid="CR89">89</xref>]. A clinical trial evaluating the long-term safety and efficacy of etanercept for treatment of pediatric psoriasis is ongoing [<xref ref-type="bibr" rid="CR111">111</xref>].</p></sec></sec><sec id="Sec19"><title>Other Biologics and Future Prospects</title><p>Other biologics that could play a role in pediatric psoriasis in the near future are adalimumab, infliximab and ustekinumab. In 2008, the FDA approved adalimumab for the treatment of JIA in children aged 4&#x000a0;years and older. Currently, this biologic is also used off-label for pediatric psoriasis, IBD and uveitis [<xref ref-type="bibr" rid="CR60">60</xref>, <xref ref-type="bibr" rid="CR106">106</xref>]. Only two case reports describe the use of adalimumab in pediatric psoriasis [<xref ref-type="bibr" rid="CR85">85</xref>]. In these patients, adalimumab was prescribed after failure of other systemic agents and demonstrated a favorable outcome [<xref ref-type="bibr" rid="CR112">112</xref>, <xref ref-type="bibr" rid="CR113">113</xref>]. A multicenter, randomized, double-blind study evaluating the efficacy of adalimumab versus methotrexate in pediatric patients aged 4&#x02013;17&#x000a0;years with chronic plaque psoriasis has been completed [<xref ref-type="bibr" rid="CR114">114</xref>], although results are not currently available. Adalimumab was recently granted marketing authorization in the EU for severe chronic plaque psoriasis in children aged 4&#x000a0;years and older who have had an inadequate response to or are inappropriate candidates for topical treatment and phototherapies.</p><p>Infliximab, which is the only TNF inhibitor administered by infusion, is FDA approved for the treatment of Crohn&#x02019;s disease in children aged 6&#x000a0;years and older [<xref ref-type="bibr" rid="CR106">106</xref>]. In pediatric psoriasis, only four anecdotal case reports are available [<xref ref-type="bibr" rid="CR85">85</xref>, <xref ref-type="bibr" rid="CR89">89</xref>, <xref ref-type="bibr" rid="CR111">111</xref>]. Ustekinumab was recently FDA approved for the treatment of adult psoriasis [<xref ref-type="bibr" rid="CR89">89</xref>]. There are currently three case reports describing the use of ustekinumab in pediatric patients with psoriasis. All had an excellent response to ustekinumab, with two achieving total clearance at week 8 [<xref ref-type="bibr" rid="CR115">115</xref>&#x02013;<xref ref-type="bibr" rid="CR117">117</xref>]. Future research is needed to determine efficacy and safety profiles and the role of these agents in the treatment of pediatric psoriasis. A phase III, multicenter, randomized, double-blind, placebo-controlled trial on the efficacy and safety of ustekinumab in the treatment of adolescents with plaque psoriasis (CADMUS trial) was recently completed. Respectively, 78.4 and 80.6&#x000a0;% of adolescents (aged 12&#x02013;18) receiving half-standard dosage (0.375&#x000a0;mg/kg) and standard dosage (0.750&#x000a0;mg/kg) achieved PASI75 at 12&#x000a0;weeks as compared with 10.8&#x000a0;% of participants receiving placebo [<xref ref-type="bibr" rid="CR111">111</xref>, <xref ref-type="bibr" rid="CR118">118</xref>].</p></sec></sec><sec id="Sec20"><title>Comorbidities in Pediatric Psoriasis</title><p>As in adult psoriasis, recent studies suggest the association of pediatric psoriasis with certain comorbidities. In an analysis of German health insurance data, a twofold increased risk of hyperlipidemia, obesity, hypertension, diabetes mellitus and rheumatoid arthritis was found in psoriasis patients under 18&#x000a0;years of age, as compared with healthy controls. Crohn&#x02019;s disease is noted four times more often as compared with unaffected controls [<xref ref-type="bibr" rid="CR1">1</xref>]. Similar results have been found in a smaller insurance company database [<xref ref-type="bibr" rid="CR119">119</xref>].</p><p>Obesity as a comorbidity of psoriasis has been the focus of much investigation. Koebnick et al. demonstrated that children who were overweight, moderately obese and extremely obese had 1.31-, 1.39- and 1.78-fold greater odds, respectively, of having psoriasis than children with normal weight [<xref ref-type="bibr" rid="CR120">120</xref>]. Further, Paller et al. demonstrated the increased risk of being overweight or obese in pediatric psoriasis in a large international cross-sectional study in 5- to 17-year-old children with psoriasis [<xref ref-type="bibr" rid="CR10">10</xref>]. The odds ratios (ORs) for obesity [body mass index (BMI) percentile &#x02265;95th] and excess adiposity (BMI percentile &#x0003e;85th) in psoriatic children were 4.29 and 2.65, respectively. More children with severe psoriasis [OR 4.92 (95&#x000a0;% CI 2.20&#x02013;10.99)] than with moderate psoriasis [OR 3.60 (95&#x000a0;% CI 1.56&#x02013;8.30)] were obese compared with control subjects. Waist circumference and waist-to-height ratio, surrogates for central adiposity and sensitive indicators of metabolic risk, were also seen more frequently increased in psoriatic children [<xref ref-type="bibr" rid="CR10">10</xref>].</p><p>The relationship between obesity and pediatric psoriasis deserves further investigation. Pediatric psoriasis has been associated with decreased quality of life as well as decreased tendency to participate in physical activities because of increased pruritus with sweating and increased visibility of the psoriatic lesions to peers [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR121">121</xref>]. These factors theoretically could contribute to pediatric obesity, but only after the occurrence of psoriasis. On the other hand, psoriasis could instead be a complication of obesity, with systemic inflammation associated with obesity predisposing to the occurrence of psoriasis [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR122">122</xref>]. Becker et al. demonstrated in a pilot study that being overweight or obese preceded psoriasis by at least 2&#x000a0;years in 93&#x000a0;% of children with psoriasis [<xref ref-type="bibr" rid="CR11">11</xref>]. In these children, percentages of immediate family members with obesity and psoriasis were 48 and 41&#x000a0;%, respectively. Although it is unclear whether weight loss reduces psoriasis severity in children, just as it remains controversial in adults, lifestyle education and weight-loss programs in these families should be recommended [<xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR123">123</xref>].</p><p>In addition to obesity, the presence of the metabolic syndrome is an issue in pediatric psoriasis patients. The metabolic syndrome in children is defined as having at least three of the following: (1) fasting triglycerides &#x02265;1.1&#x000a0;mmol/L; (2) high-density lipoprotein &#x0003c;1.3&#x000a0;mmol/L, except in boys aged 15&#x02013;19&#x000a0;years, in whom the cut-off point is &#x0003c;1.2&#x000a0;mmol/L; (3) fasting glucose &#x02265;6.1&#x000a0;mmol/L; (4) waist circumference &#x0003e;75th percentile for age and gender; and (5) systolic blood pressure &#x0003e;90th percentile for gender, age and height (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>) [<xref ref-type="bibr" rid="CR124">124</xref>]. In a small study in 20 children, the prevalence of metabolic syndrome was significantly higher in pediatric psoriasis patients (30&#x000a0;%) compared with the age- and gender-matched control subjects (7.4&#x000a0;%). No differences in BMI or individual components of metabolic syndrome were found [<xref ref-type="bibr" rid="CR125">125</xref>]. Childhood onset of psoriasis does not seem to be an additional risk factor for the higher prevalence of metabolic comorbidities and cardiovascular disease in adulthood [<xref ref-type="bibr" rid="CR126">126</xref>].<fig id="Fig1"><label>Fig.&#x000a0;1</label><caption><p>Pediatric definition of the metabolic syndrome. Figure adapted from de Ferranti et al. [<xref ref-type="bibr" rid="CR124">124</xref>]</p></caption><graphic xlink:href="40272_2015_137_Fig1_HTML" id="MO1"/></fig></p><p>Pediatric psoriasis could have detrimental effects on quality of life. Because of substantial developmental changes in early life, children are a vulnerable group. Psoriasis can disrupt their social relationships and interfere with school and sport [<xref ref-type="bibr" rid="CR7">7</xref>]. The Children Dermatology Life Quality Index (CDLQI) was developed to allow quality-of-life assessment in children with psoriasis and other skin disorders [<xref ref-type="bibr" rid="CR127">127</xref>]. Oostveen et al. conducted a prospective observational study of children with psoriasis from a registry containing daily clinical practice data [<xref ref-type="bibr" rid="CR9">9</xref>]. They assessed the CDLQI in a cohort of 125 patients, finding that psoriasis has a negative impact on quality of life. The questions related to itching and their treatment regimens seemed to have the highest impact on the quality of life of these children. Effective interventions had a positive effect on quality of life, primarily through improving complaints of itch and sleep disturbance [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR128">128</xref>].</p><p>Previous research in adult populations reported psychiatric symptoms and diagnoses, such as depression and anxiety, in up to 60&#x000a0;% of psoriasis patients. Although studies regarding psychiatric symptoms in pediatric psoriasis are limited, it is known that pain, itching and the visible psoriasis lesions can result in embarrassment, social discomfort and anxiety in pediatric psoriasis patients [<xref ref-type="bibr" rid="CR129">129</xref>, <xref ref-type="bibr" rid="CR130">130</xref>]. In line with these findings, Kimball et al. demonstrated an increased risk of developing depression, anxiety and bipolar disorder in psoriatic children compared with control subjects [<xref ref-type="bibr" rid="CR12">12</xref>]. In addition, children suffering from psoriasis had a 47&#x000a0;% greater risk of taking psychotropic medications. Since the rate of antidepressant and anxiolytic medication use is higher than the incidences of depression and anxiety disorder in this study, and psychotropic medications are more likely to be used for more severe cases, the true incidence of psychiatric diagnoses may be even higher [<xref ref-type="bibr" rid="CR12">12</xref>]. The relationship between psoriasis and depression and impaired quality of life in children has also been reported by other research groups [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR131">131</xref>].</p></sec><sec id="Sec21"><title>Conclusion</title><p>Psoriasis begins in childhood in almost one-third of the cases and is increasing in prevalence and incidence. However, the evidence on treatment efficacy and safety is still limited, and long-term data in pediatric patients are lacking. A prospective, multicenter, international registry is needed to evaluate these treatments in a standardized manner and ultimately to develop international guidelines on pediatric psoriasis.</p></sec></body><back><ack><title>Conflict of interest</title><p>IMGJ Bronckers declares no conflict of interest. AS Paller was an investigator without honorarium for AbbVie, Amgen and Stiefel/GSK, and was a consultant and received honorarium from AbbVie and Celgene. MMB Seyger received grants from/was involved in clinical trials from AbbVie, Almirall, Astellas, Leo Pharma, and Pfizer, and has served as a consultant for AbbVie, Almirall, Boehringer Ingelheim, Celgene and Pfizer. PCM van de Kerkhof has carried out clinical trials for Centocor, Pfizer, Schering Plough, AbbVie, Philips Lighting, Novartis, GSK, Eli Lilly, Amgen and Almirall, and has consultancy services for Schering Plough, Celgene, Centocor, Almirall, Pfizer, AbbVie, Actelion, Galderma, Novartis, and Janssen. MJ van Geel has carried out clinical trials for AbbVie, Astellas, Leo Pharma, and Pfizer, and has received speaking fees from MSD and reimbursement for attending a symposium from Pfizer and Janssen.</p><sec id="d30e1210"><title>Funding/support</title><p>No funding has been received for the preparation of this manuscript.</p></sec></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Augustin</surname><given-names>M</given-names></name><name><surname>Glaeske</surname><given-names>G</given-names></name><name><surname>Radtke</surname><given-names>MA</given-names></name><name><surname>Christophers</surname><given-names>E</given-names></name><name><surname>Reich</surname><given-names>K</given-names></name><name><surname>Schafer</surname><given-names>I</given-names></name></person-group><article-title>Epidemiology and comorbidity of psoriasis in children</article-title><source>Br J Dermat</source><year>2010</year><volume>162</volume><issue>3</issue><fpage>633</fpage><lpage>636</lpage></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Christophers</surname><given-names>E</given-names></name></person-group><article-title>Psoriasis&#x02014;epidemiology and clinical spectrum</article-title><source>Clin Exp Dermatol</source><year>2001</year><volume>26</volume><issue>4</issue><fpage>314</fpage><lpage>320</lpage><pub-id pub-id-type="pmid">11422182</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parisi</surname><given-names>R</given-names></name><name><surname>Symmons</surname><given-names>DP</given-names></name><name><surname>Griffiths</surname><given-names>CE</given-names></name><name><surname>Ashcroft</surname><given-names>DM</given-names></name></person-group><article-title>Identification, Management of Psoriasis and Associated Comorbidity Project. Global epidemiology of psoriasis: a systematic review of incidence and prevalence</article-title><source>J Invest Dermatol</source><year>2013</year><volume>133</volume><issue>2</issue><fpage>377</fpage><lpage>385</lpage><pub-id pub-id-type="pmid">23014338</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gelfand</surname><given-names>JM</given-names></name><name><surname>Weinstein</surname><given-names>R</given-names></name><name><surname>Porter</surname><given-names>SB</given-names></name><name><surname>Neimann</surname><given-names>AL</given-names></name><name><surname>Berlin</surname><given-names>JA</given-names></name><name><surname>Margolis</surname><given-names>DJ</given-names></name></person-group><article-title>Prevalence and treatment of psoriasis in the United Kingdom: a population-based study</article-title><source>Arch Dermatol</source><year>2005</year><volume>141</volume><issue>12</issue><fpage>1537</fpage><lpage>1541</lpage><pub-id pub-id-type="pmid">16365254</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Raychaudhuri</surname><given-names>SP</given-names></name><name><surname>Gross</surname><given-names>J</given-names></name></person-group><article-title>A comparative study of pediatric onset psoriasis with adult onset psoriasis</article-title><source>Pediatr Dermatol.</source><year>2000</year><volume>17</volume><issue>3</issue><fpage>174</fpage><lpage>178</lpage><pub-id pub-id-type="pmid">10886746</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tollefson</surname><given-names>MM</given-names></name><name><surname>Crowson</surname><given-names>CS</given-names></name><name><surname>McEvoy</surname><given-names>MT</given-names></name><name><surname>Maradit Kremers</surname><given-names>H</given-names></name></person-group><article-title>Incidence of psoriasis in children: a population-based study</article-title><source>J Am Acad Dermatol</source><year>2010</year><volume>62</volume><issue>6</issue><fpage>979</fpage><lpage>987</lpage><pub-id pub-id-type="pmid">19962785</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Jager</surname><given-names>ME</given-names></name><name><surname>De Jong</surname><given-names>EM</given-names></name><name><surname>Evers</surname><given-names>AW</given-names></name><name><surname>Van De Kerkhof</surname><given-names>PC</given-names></name><name><surname>Seyger</surname><given-names>MM</given-names></name></person-group><article-title>The burden of childhood psoriasis</article-title><source>Pediatr Dermatol</source><year>2011</year><volume>28</volume><issue>6</issue><fpage>736</fpage><lpage>737</lpage><pub-id pub-id-type="pmid">21692835</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bilgic</surname><given-names>A</given-names></name><name><surname>Bilgic</surname><given-names>O</given-names></name><name><surname>Akis</surname><given-names>HK</given-names></name><name><surname>Eskioglu</surname><given-names>F</given-names></name><name><surname>Kilic</surname><given-names>EZ</given-names></name></person-group><article-title>Psychiatric symptoms and health-related quality of life in children and adolescents with psoriasis</article-title><source>Pediatr Dermatol</source><year>2010</year><volume>27</volume><issue>6</issue><fpage>614</fpage><lpage>617</lpage><pub-id pub-id-type="pmid">21078106</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oostveen</surname><given-names>AM</given-names></name><name><surname>de Jager</surname><given-names>ME</given-names></name><name><surname>van de Kerkhof</surname><given-names>PC</given-names></name><name><surname>Donders</surname><given-names>AR</given-names></name><name><surname>de Jong</surname><given-names>EM</given-names></name><name><surname>Seyger</surname><given-names>MM</given-names></name></person-group><article-title>The influence of treatments in daily clinical practice on the Children&#x02019;s Dermatology Life Quality Index in juvenile psoriasis: a longitudinal study from the Child-CAPTURE patient registry</article-title><source>Br J Dermatol</source><year>2012</year><volume>167</volume><issue>1</issue><fpage>145</fpage><lpage>149</lpage><pub-id pub-id-type="pmid">22616669</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paller</surname><given-names>AS</given-names></name><name><surname>Mercy</surname><given-names>K</given-names></name><name><surname>Kwasny</surname><given-names>MJ</given-names></name><name><surname>Choon</surname><given-names>SE</given-names></name><name><surname>Cordoro</surname><given-names>KM</given-names></name><name><surname>Girolomoni</surname><given-names>G</given-names></name><etal/></person-group><article-title>Association of pediatric psoriasis severity with excess and central adiposity: an international cross-sectional study</article-title><source>JAMA Dermatol</source><year>2013</year><volume>149</volume><issue>2</issue><fpage>166</fpage><lpage>176</lpage><pub-id pub-id-type="pmid">23560297</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Becker</surname><given-names>L</given-names></name><name><surname>Tom</surname><given-names>WL</given-names></name><name><surname>Eshagh</surname><given-names>K</given-names></name><name><surname>Benjamin</surname><given-names>LT</given-names></name><name><surname>Paller</surname><given-names>AS</given-names></name></person-group><article-title>Excess adiposity preceding pediatric psoriasis</article-title><source>JAMA Dermatol</source><year>2014</year><volume>150</volume><issue>5</issue><fpage>573</fpage><lpage>574</lpage><pub-id pub-id-type="pmid">24695974</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kimball</surname><given-names>AB</given-names></name><name><surname>Wu</surname><given-names>EQ</given-names></name><name><surname>Guerin</surname><given-names>A</given-names></name><name><surname>Yu</surname><given-names>AP</given-names></name><name><surname>Tsaneva</surname><given-names>M</given-names></name><name><surname>Gupta</surname><given-names>SR</given-names></name><etal/></person-group><article-title>Risks of developing psychiatric disorders in pediatric patients with psoriasis</article-title><source>J Am Acad Dermatol.</source><year>2012</year><volume>67</volume><issue>4</issue><fpage>651</fpage><lpage>657</lpage><pub-id pub-id-type="pmid">22243764</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Jager</surname><given-names>ME</given-names></name><name><surname>Van de Kerkhof</surname><given-names>PC</given-names></name><name><surname>De Jong</surname><given-names>EM</given-names></name><name><surname>Seyger</surname><given-names>MM</given-names></name></person-group><article-title>Epidemiology and prescribed treatments in childhood psoriasis: a survey among medical professionals</article-title><source>J Dermatol Treat</source><year>2009</year><volume>20</volume><issue>5</issue><fpage>254</fpage><lpage>258</lpage></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matusiewicz</surname><given-names>D</given-names></name><name><surname>Koerber</surname><given-names>A</given-names></name><name><surname>Schadendorf</surname><given-names>D</given-names></name><name><surname>Wasem</surname><given-names>J</given-names></name><name><surname>Neumann</surname><given-names>A</given-names></name></person-group><article-title>Childhood psoriasis&#x02014;an analysis of German health insurance data</article-title><source>Pediatr Dermatol</source><year>2014</year><volume>31</volume><issue>1</issue><fpage>8</fpage><lpage>13</lpage><pub-id pub-id-type="pmid">24111584</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>YC</given-names></name><name><surname>Cheng</surname><given-names>YW</given-names></name><name><surname>Lai</surname><given-names>CS</given-names></name><name><surname>Chen</surname><given-names>W</given-names></name></person-group><article-title>Prevalence of childhood acne, ephelides, warts, atopic dermatitis, psoriasis, alopecia areata and keloid in Kaohsiung County, Taiwan: a community-based clinical survey</article-title><source>J Eur Acad Dermatol Venereol: JEADV</source><year>2007</year><volume>21</volume><issue>5</issue><fpage>643</fpage><lpage>649</lpage><pub-id pub-id-type="pmid">17447978</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>GY</given-names></name><name><surname>Cheng</surname><given-names>YW</given-names></name><name><surname>Wang</surname><given-names>CY</given-names></name><name><surname>Hsu</surname><given-names>TJ</given-names></name><name><surname>Hsu</surname><given-names>MM</given-names></name><name><surname>Yang</surname><given-names>PT</given-names></name><etal/></person-group><article-title>Prevalence of skin diseases among schoolchildren in Magong, Penghu, Taiwan: a community-based clinical survey. Journal of the Formosan Medical Association =</article-title><source>Taiwan yi zhi</source><year>2008</year><volume>107</volume><issue>1</issue><fpage>21</fpage><lpage>29</lpage><pub-id pub-id-type="pmid">18218574</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Griffiths</surname><given-names>CE</given-names></name><name><surname>Barker</surname><given-names>JN</given-names></name></person-group><article-title>Pathogenesis and clinical features of psoriasis</article-title><source>Lancet</source><year>2007</year><volume>370</volume><issue>9583</issue><fpage>263</fpage><lpage>271</lpage><pub-id pub-id-type="pmid">17658397</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsankov</surname><given-names>N</given-names></name><name><surname>Angelova</surname><given-names>I</given-names></name><name><surname>Kazandjieva</surname><given-names>J</given-names></name></person-group><article-title>Drug-induced psoriasis. Recognition and management</article-title><source>Am J Clin Dermatol</source><year>2000</year><volume>1</volume><issue>3</issue><fpage>159</fpage><lpage>165</lpage><pub-id pub-id-type="pmid">11702297</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cullen</surname><given-names>G</given-names></name><name><surname>Kroshinsky</surname><given-names>D</given-names></name><name><surname>Cheifetz</surname><given-names>AS</given-names></name><name><surname>Korzenik</surname><given-names>JR</given-names></name></person-group><article-title>Psoriasis associated with anti-tumour necrosis factor therapy in inflammatory bowel disease: a new series and a review of 120 cases from the literature</article-title><source>Aliment Pharmacol Ther</source><year>2011</year><volume>34</volume><issue>11&#x02013;12</issue><fpage>1318</fpage><lpage>1327</lpage><pub-id pub-id-type="pmid">21957906</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perman</surname><given-names>MJ</given-names></name><name><surname>Lovell</surname><given-names>DJ</given-names></name><name><surname>Denson</surname><given-names>LA</given-names></name><name><surname>Farrell</surname><given-names>MK</given-names></name><name><surname>Lucky</surname><given-names>AW</given-names></name></person-group><article-title>Five cases of anti-tumor necrosis factor alpha-induced psoriasis presenting with severe scalp involvement in children</article-title><source>Pediatr Dermatol</source><year>2012</year><volume>29</volume><issue>4</issue><fpage>454</fpage><lpage>459</lpage><pub-id pub-id-type="pmid">21995665</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fan</surname><given-names>X</given-names></name><name><surname>Xiao</surname><given-names>FL</given-names></name><name><surname>Yang</surname><given-names>S</given-names></name><name><surname>Liu</surname><given-names>JB</given-names></name><name><surname>Yan</surname><given-names>KL</given-names></name><name><surname>Liang</surname><given-names>YH</given-names></name><etal/></person-group><article-title>Childhood psoriasis: a study of 277 patients from China</article-title><source>J Eur Acad Dermatol Venereol: JEADV</source><year>2007</year><volume>21</volume><issue>6</issue><fpage>762</fpage><lpage>765</lpage><pub-id pub-id-type="pmid">17567304</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kumar</surname><given-names>B</given-names></name><name><surname>Jain</surname><given-names>R</given-names></name><name><surname>Sandhu</surname><given-names>K</given-names></name><name><surname>Kaur</surname><given-names>I</given-names></name><name><surname>Handa</surname><given-names>S</given-names></name></person-group><article-title>Epidemiology of childhood psoriasis: a study of 419 patients from northern India</article-title><source>Int J Dermatol</source><year>2004</year><volume>43</volume><issue>9</issue><fpage>654</fpage><lpage>658</lpage><pub-id pub-id-type="pmid">15357744</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morris</surname><given-names>A</given-names></name><name><surname>Rogers</surname><given-names>M</given-names></name><name><surname>Fischer</surname><given-names>G</given-names></name><name><surname>Williams</surname><given-names>K</given-names></name></person-group><article-title>Childhood psoriasis: a clinical review of 1262 cases</article-title><source>Pediatr Dermatol</source><year>2001</year><volume>18</volume><issue>3</issue><fpage>188</fpage><lpage>198</lpage><pub-id pub-id-type="pmid">11437997</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nanda</surname><given-names>A</given-names></name><name><surname>Kaur</surname><given-names>S</given-names></name><name><surname>Kaur</surname><given-names>I</given-names></name><name><surname>Kumar</surname><given-names>B</given-names></name></person-group><article-title>Childhood psoriasis: an epidemiologic survey of 112 patients</article-title><source>Pediatr Dermatol</source><year>1990</year><volume>7</volume><issue>1</issue><fpage>19</fpage><lpage>21</lpage><pub-id pub-id-type="pmid">2343003</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mercy</surname><given-names>K</given-names></name><name><surname>Kwasny</surname><given-names>M</given-names></name><name><surname>Cordoro</surname><given-names>KM</given-names></name><name><surname>Menter</surname><given-names>A</given-names></name><name><surname>Tom</surname><given-names>WL</given-names></name><name><surname>Korman</surname><given-names>N</given-names></name><etal/></person-group><article-title>Clinical manifestations of pediatric psoriasis: results of a multicenter study in the United States</article-title><source>Pediatr Dermatol</source><year>2013</year><volume>30</volume><issue>4</issue><fpage>424</fpage><lpage>428</lpage><pub-id pub-id-type="pmid">23360462</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chiam</surname><given-names>LY</given-names></name><name><surname>de Jager</surname><given-names>ME</given-names></name><name><surname>Giam</surname><given-names>YC</given-names></name><name><surname>de Jong</surname><given-names>EM</given-names></name><name><surname>van de Kerkhof</surname><given-names>PC</given-names></name><name><surname>Seyger</surname><given-names>MM</given-names></name></person-group><article-title>Juvenile psoriasis in European and Asian children: similarities and differences</article-title><source>Br J Dermatol</source><year>2011</year><volume>164</volume><issue>5</issue><fpage>1101</fpage><lpage>1103</lpage><pub-id pub-id-type="pmid">21418172</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>al-Fouzan</surname><given-names>AS</given-names></name><name><surname>Nanda</surname><given-names>A</given-names></name></person-group><article-title>A survey of childhood psoriasis in Kuwait</article-title><source>Pediatr Dermatol</source><year>1994</year><volume>11</volume><issue>2</issue><fpage>116</fpage><lpage>119</lpage><pub-id pub-id-type="pmid">8041649</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seyhan</surname><given-names>M</given-names></name><name><surname>Coskun</surname><given-names>BK</given-names></name><name><surname>Saglam</surname><given-names>H</given-names></name><name><surname>Ozcan</surname><given-names>H</given-names></name><name><surname>Karincaoglu</surname><given-names>Y</given-names></name></person-group><article-title>Psoriasis in childhood and adolescence: evaluation of demographic and clinical features</article-title><source>Pediatr Int</source><year>2006</year><volume>48</volume><issue>6</issue><fpage>525</fpage><lpage>530</lpage><pub-id pub-id-type="pmid">17168968</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shah</surname><given-names>KN</given-names></name></person-group><article-title>Diagnosis and treatment of pediatric psoriasis: current and future</article-title><source>Am J Clin Dermatol</source><year>2013</year><volume>14</volume><issue>3</issue><fpage>195</fpage><lpage>213</lpage><pub-id pub-id-type="pmid">23677694</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kwon</surname><given-names>HH</given-names></name><name><surname>Na</surname><given-names>SJ</given-names></name><name><surname>Jo</surname><given-names>SJ</given-names></name><name><surname>Youn</surname><given-names>JI</given-names></name></person-group><article-title>Epidemiology and clinical features of pediatric psoriasis in tertiary referral psoriasis clinic</article-title><source>J Dermatol</source><year>2012</year><volume>39</volume><issue>3</issue><fpage>260</fpage><lpage>264</lpage><pub-id pub-id-type="pmid">22211370</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dogra</surname><given-names>S</given-names></name><name><surname>Kaur</surname><given-names>I</given-names></name></person-group><article-title>Childhood psoriasis</article-title><source>Indian J Dermatol Venereol Leprol</source><year>2010</year><volume>76</volume><issue>4</issue><fpage>357</fpage><lpage>365</lpage><pub-id pub-id-type="pmid">20657115</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tollefson</surname><given-names>MM</given-names></name></person-group><article-title>Diagnosis and management of psoriasis in children</article-title><source>Pediatr Clin North Am</source><year>2014</year><volume>61</volume><issue>2</issue><fpage>261</fpage><lpage>277</lpage><pub-id pub-id-type="pmid">24636645</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Benoit</surname><given-names>S</given-names></name><name><surname>Hamm</surname><given-names>H</given-names></name></person-group><article-title>Childhood psoriasis</article-title><source>Clin Dermatol</source><year>2007</year><volume>25</volume><issue>6</issue><fpage>555</fpage><lpage>562</lpage><pub-id pub-id-type="pmid">18021892</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Silverberg</surname><given-names>NB</given-names></name></person-group><article-title>Pediatric psoriasis: an update</article-title><source>Ther Clin Risk Manag</source><year>2009</year><volume>5</volume><fpage>849</fpage><lpage>856</lpage><pub-id pub-id-type="pmid">19898649</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Howard</surname><given-names>R</given-names></name><name><surname>Tsuchiya</surname><given-names>A</given-names></name></person-group><article-title>Adult skin disease in the pediatric patient</article-title><source>Dermatol Clin</source><year>1998</year><volume>16</volume><issue>3</issue><fpage>593</fpage><lpage>608</lpage><pub-id pub-id-type="pmid">9704214</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Busch</surname><given-names>AL</given-names></name><name><surname>Landau</surname><given-names>JM</given-names></name><name><surname>Moody</surname><given-names>MN</given-names></name><name><surname>Goldberg</surname><given-names>LH</given-names></name></person-group><article-title>Pediatric psoriasis</article-title><source>Skin Therapy Lett</source><year>2012</year><volume>17</volume><issue>1</issue><fpage>5</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">22358228</pub-id></element-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martin</surname><given-names>BA</given-names></name><name><surname>Chalmers</surname><given-names>RJ</given-names></name><name><surname>Telfer</surname><given-names>NR</given-names></name></person-group><article-title>How great is the risk of further psoriasis following a single episode of acute guttate psoriasis?</article-title><source>Arch Dermatol</source><year>1996</year><volume>132</volume><issue>6</issue><fpage>717</fpage><lpage>718</lpage><pub-id pub-id-type="pmid">8651734</pub-id></element-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Setta-Kaffetzi</surname><given-names>N</given-names></name><name><surname>Navarini</surname><given-names>AA</given-names></name><name><surname>Patel</surname><given-names>VM</given-names></name><name><surname>Pullabhatla</surname><given-names>V</given-names></name><name><surname>Pink</surname><given-names>AE</given-names></name><name><surname>Choon</surname><given-names>SE</given-names></name><etal/></person-group><article-title>Rare pathogenic variants in IL36RN underlie a spectrum of psoriasis-associated pustular phenotypes</article-title><source>J Invest Dermatol</source><year>2013</year><volume>133</volume><issue>5</issue><fpage>1366</fpage><lpage>1369</lpage><pub-id pub-id-type="pmid">23303454</pub-id></element-citation></ref><ref id="CR39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liao</surname><given-names>PB</given-names></name><name><surname>Rubinson</surname><given-names>R</given-names></name><name><surname>Howard</surname><given-names>R</given-names></name><name><surname>Sanchez</surname><given-names>G</given-names></name><name><surname>Frieden</surname><given-names>IJ</given-names></name></person-group><article-title>Annular pustular psoriasis&#x02014;most common form of pustular psoriasis in children: report of three cases and review of the literature</article-title><source>Pediatr Dermatol</source><year>2002</year><volume>19</volume><issue>1</issue><fpage>19</fpage><lpage>25</lpage><pub-id pub-id-type="pmid">11860564</pub-id></element-citation></ref><ref id="CR40"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brazzelli</surname><given-names>V</given-names></name><name><surname>Carugno</surname><given-names>A</given-names></name><name><surname>Alborghetti</surname><given-names>A</given-names></name><name><surname>Grasso</surname><given-names>V</given-names></name><name><surname>Cananzi</surname><given-names>R</given-names></name><name><surname>Fornara</surname><given-names>L</given-names></name><etal/></person-group><article-title>Prevalence, severity and clinical features of psoriasis in fingernails and toenails in adult patients: Italian experience</article-title><source>J Eur Acad Dermatol Venereol: JEADV</source><year>2012</year><volume>26</volume><issue>11</issue><fpage>1354</fpage><lpage>1359</lpage><pub-id pub-id-type="pmid">21973119</pub-id></element-citation></ref><ref id="CR41"><label>41.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Schachner</surname><given-names>LA</given-names></name><name><surname>Hansen</surname><given-names>RC</given-names></name></person-group><source>Pediatric dermatology</source><year>2011</year><edition>4</edition><publisher-loc>Philadelphia</publisher-loc><publisher-name>Elsevier Ltd</publisher-name></element-citation></ref><ref id="CR42"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stoll</surname><given-names>ML</given-names></name><name><surname>Zurakowski</surname><given-names>D</given-names></name><name><surname>Nigrovic</surname><given-names>LE</given-names></name><name><surname>Nichols</surname><given-names>DP</given-names></name><name><surname>Sundel</surname><given-names>RP</given-names></name><name><surname>Nigrovic</surname><given-names>PA</given-names></name></person-group><article-title>Patients with juvenile psoriatic arthritis comprise two distinct populations</article-title><source>Arthritis Rheum</source><year>2006</year><volume>54</volume><issue>11</issue><fpage>3564</fpage><lpage>3572</lpage><pub-id pub-id-type="pmid">17075862</pub-id></element-citation></ref><ref id="CR43"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Flato</surname><given-names>B</given-names></name><name><surname>Lien</surname><given-names>G</given-names></name><name><surname>Smerdel-Ramoya</surname><given-names>A</given-names></name><name><surname>Vinje</surname><given-names>O</given-names></name></person-group><article-title>Juvenile psoriatic arthritis: longterm outcome and differentiation from other subtypes of juvenile idiopathic arthritis</article-title><source>J Rheumatol</source><year>2009</year><volume>36</volume><issue>3</issue><fpage>642</fpage><lpage>650</lpage><pub-id pub-id-type="pmid">19208605</pub-id></element-citation></ref><ref id="CR44"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krumrey-Langkammerer</surname><given-names>M</given-names></name><name><surname>Hafner</surname><given-names>R</given-names></name></person-group><article-title>Evaluation of the ILAR criteria for juvenile idiopathic arthritis</article-title><source>J Rheumatol</source><year>2001</year><volume>28</volume><issue>11</issue><fpage>2544</fpage><lpage>2547</lpage><pub-id pub-id-type="pmid">11708431</pub-id></element-citation></ref><ref id="CR45"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saurenmann</surname><given-names>RK</given-names></name><name><surname>Levin</surname><given-names>AV</given-names></name><name><surname>Feldman</surname><given-names>BM</given-names></name><name><surname>Rose</surname><given-names>JB</given-names></name><name><surname>Laxer</surname><given-names>RM</given-names></name><name><surname>Schneider</surname><given-names>R</given-names></name><etal/></person-group><article-title>Prevalence, risk factors, and outcome of uveitis in juvenile idiopathic arthritis: a long-term followup study</article-title><source>Arthritis Rheum</source><year>2007</year><volume>56</volume><issue>2</issue><fpage>647</fpage><lpage>657</lpage><pub-id pub-id-type="pmid">17265500</pub-id></element-citation></ref><ref id="CR46"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Danner</surname><given-names>S</given-names></name><name><surname>Sordet</surname><given-names>C</given-names></name><name><surname>Terzic</surname><given-names>J</given-names></name><name><surname>Donato</surname><given-names>L</given-names></name><name><surname>Velten</surname><given-names>M</given-names></name><name><surname>Fischbach</surname><given-names>M</given-names></name><etal/></person-group><article-title>Epidemiology of juvenile idiopathic arthritis in Alsace, France</article-title><source>J Rheumatol</source><year>2006</year><volume>33</volume><issue>7</issue><fpage>1377</fpage><lpage>1381</lpage><pub-id pub-id-type="pmid">16821272</pub-id></element-citation></ref><ref id="CR47"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Butbul Aviel</surname><given-names>Y</given-names></name><name><surname>Tyrrell</surname><given-names>P</given-names></name><name><surname>Schneider</surname><given-names>R</given-names></name><name><surname>Dhillon</surname><given-names>S</given-names></name><name><surname>Feldman</surname><given-names>BM</given-names></name><name><surname>Laxer</surname><given-names>R</given-names></name><etal/></person-group><article-title>Juvenile psoriatic arthritis (JPsA): juvenile arthritis with psoriasis?</article-title><source>Pediatr Rheumatol Online J</source><year>2013</year><volume>11</volume><issue>1</issue><fpage>11</fpage><pub-id pub-id-type="pmid">23497068</pub-id></element-citation></ref><ref id="CR48"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sticherling</surname><given-names>M</given-names></name><name><surname>Minden</surname><given-names>K</given-names></name><name><surname>Kuster</surname><given-names>RM</given-names></name><name><surname>Krause</surname><given-names>A</given-names></name><name><surname>Borte</surname><given-names>M</given-names></name></person-group><article-title>Psoriasis and psoriasis arthritis in childhood and adolescence. Overview and consensus statement of the 9th Worlitz Expert Round Table Discussion 2006 for the Society for Child and Adolescent Rheumatology</article-title><source>Z Rheumatol</source><year>2007</year><volume>66</volume><issue>4</issue><fpage>349</fpage><lpage>354</lpage><pub-id pub-id-type="pmid">17623119</pub-id></element-citation></ref><ref id="CR49"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zachariae</surname><given-names>H</given-names></name></person-group><article-title>Prevalence of joint disease in patients with psoriasis: implications for therapy</article-title><source>Am J Clin Dermatol</source><year>2003</year><volume>4</volume><issue>7</issue><fpage>441</fpage><lpage>447</lpage><pub-id pub-id-type="pmid">12814334</pub-id></element-citation></ref><ref id="CR50"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wittkowski</surname><given-names>KM</given-names></name><name><surname>Leonardi</surname><given-names>C</given-names></name><name><surname>Gottlieb</surname><given-names>A</given-names></name><name><surname>Menter</surname><given-names>A</given-names></name><name><surname>Krueger</surname><given-names>GG</given-names></name><name><surname>Tebbey</surname><given-names>PW</given-names></name><etal/></person-group><article-title>Clinical symptoms of skin, nails, and joints manifest independently in patients with concomitant psoriasis and psoriatic arthritis</article-title><source>PLoS One</source><year>2011</year><volume>6</volume><issue>6</issue><fpage>e20279</fpage><pub-id pub-id-type="pmid">21673809</pub-id></element-citation></ref><ref id="CR51"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nestle</surname><given-names>FO</given-names></name><name><surname>Kaplan</surname><given-names>DH</given-names></name><name><surname>Barker</surname><given-names>J</given-names></name></person-group><article-title>Psoriasis</article-title><source>N Engl J Med</source><year>2009</year><volume>361</volume><issue>5</issue><fpage>496</fpage><lpage>509</lpage><pub-id pub-id-type="pmid">19641206</pub-id></element-citation></ref><ref id="CR52"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murphy</surname><given-names>M</given-names></name><name><surname>Kerr</surname><given-names>P</given-names></name><name><surname>Grant-Kels</surname><given-names>JM</given-names></name></person-group><article-title>The histopathologic spectrum of psoriasis</article-title><source>Clin Dermatol</source><year>2007</year><volume>25</volume><issue>6</issue><fpage>524</fpage><lpage>528</lpage><pub-id pub-id-type="pmid">18021888</pub-id></element-citation></ref><ref id="CR53"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stahle</surname><given-names>M</given-names></name><name><surname>Atakan</surname><given-names>N</given-names></name><name><surname>Boehncke</surname><given-names>WH</given-names></name><name><surname>Chimenti</surname><given-names>S</given-names></name><name><surname>Dauden</surname><given-names>E</given-names></name><name><surname>Giannetti</surname><given-names>A</given-names></name><etal/></person-group><article-title>Juvenile psoriasis and its clinical management: a European expert group consensus</article-title><source>J Ger Soc Dermatol</source><year>2010</year><volume>8</volume><issue>10</issue><fpage>812</fpage><lpage>818</lpage></element-citation></ref><ref id="CR54"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moscarella</surname><given-names>E</given-names></name><name><surname>Longo</surname><given-names>C</given-names></name><name><surname>Zalaudek</surname><given-names>I</given-names></name><name><surname>Argenziano</surname><given-names>G</given-names></name><name><surname>Piana</surname><given-names>S</given-names></name><name><surname>Lallas</surname><given-names>A</given-names></name></person-group><article-title>Dermoscopy and confocal microscopy clues in the diagnosis of psoriasis and porokeratosis</article-title><source>J Am Acad Dermatol</source><year>2013</year><volume>69</volume><issue>5</issue><fpage>e231</fpage><lpage>e233</lpage><pub-id pub-id-type="pmid">24124843</pub-id></element-citation></ref><ref id="CR55"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lallas</surname><given-names>A</given-names></name><name><surname>Kyrgidis</surname><given-names>A</given-names></name><name><surname>Tzellos</surname><given-names>TG</given-names></name><name><surname>Apalla</surname><given-names>Z</given-names></name><name><surname>Karakyriou</surname><given-names>E</given-names></name><name><surname>Karatolias</surname><given-names>A</given-names></name><etal/></person-group><article-title>Accuracy of dermoscopic criteria for the diagnosis of psoriasis, dermatitis, lichen planus and pityriasis rosea</article-title><source>Br J Dermatol</source><year>2012</year><volume>166</volume><issue>6</issue><fpage>1198</fpage><lpage>1205</lpage><pub-id pub-id-type="pmid">22296226</pub-id></element-citation></ref><ref id="CR56"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luersen</surname><given-names>K</given-names></name><name><surname>Davis</surname><given-names>SA</given-names></name><name><surname>Kaplan</surname><given-names>SG</given-names></name><name><surname>Abel</surname><given-names>TD</given-names></name><name><surname>Winchester</surname><given-names>WW</given-names></name><name><surname>Feldman</surname><given-names>SR</given-names></name></person-group><article-title>Sticker charts: a method for improving adherence to treatment of chronic diseases in children</article-title><source>Pediatr Dermatol</source><year>2012</year><volume>29</volume><issue>4</issue><fpage>403</fpage><lpage>408</lpage><pub-id pub-id-type="pmid">22471987</pub-id></element-citation></ref><ref id="CR57"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tan</surname><given-names>X</given-names></name><name><surname>Feldman</surname><given-names>SR</given-names></name><name><surname>Chang</surname><given-names>J</given-names></name><name><surname>Balkrishnan</surname><given-names>R</given-names></name></person-group><article-title>Topical drug delivery systems in dermatology: a review of patient adherence issues</article-title><source>Expert Opin Drug Deliv</source><year>2012</year><volume>9</volume><issue>10</issue><fpage>1263</fpage><lpage>1271</lpage><pub-id pub-id-type="pmid">22861153</pub-id></element-citation></ref><ref id="CR58"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davis</surname><given-names>SA</given-names></name><name><surname>Lin</surname><given-names>HC</given-names></name><name><surname>Yu</surname><given-names>CH</given-names></name><name><surname>Balkrishnan</surname><given-names>R</given-names></name><name><surname>Feldman</surname><given-names>SR</given-names></name></person-group><article-title>Underuse of early follow-up visits: a missed opportunity to improve patients&#x02019; adherence</article-title><source>J Drugs Dermatol: JDD</source><year>2014</year><volume>13</volume><issue>7</issue><fpage>833</fpage><lpage>836</lpage><pub-id pub-id-type="pmid">25007367</pub-id></element-citation></ref><ref id="CR59"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lara-Corrales</surname><given-names>I</given-names></name><name><surname>Xi</surname><given-names>N</given-names></name><name><surname>Pope</surname><given-names>E</given-names></name></person-group><article-title>Childhood psoriasis treatment: evidence published over the last 5 years</article-title><source>Rev Recent Clin Trials</source><year>2011</year><volume>6</volume><issue>1</issue><fpage>36</fpage><lpage>43</lpage><pub-id pub-id-type="pmid">20868348</pub-id></element-citation></ref><ref id="CR60"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fotiadou</surname><given-names>C</given-names></name><name><surname>Lazaridou</surname><given-names>E</given-names></name><name><surname>Ioannides</surname><given-names>D</given-names></name></person-group><article-title>Management of psoriasis in adolescence</article-title><source>Adolesc Health Med Ther</source><year>2014</year><volume>5</volume><fpage>25</fpage><lpage>34</lpage><pub-id pub-id-type="pmid">24729738</pub-id></element-citation></ref><ref id="CR61"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sticherling</surname><given-names>M</given-names></name><name><surname>Augustin</surname><given-names>M</given-names></name><name><surname>Boehncke</surname><given-names>WH</given-names></name><name><surname>Christophers</surname><given-names>E</given-names></name><name><surname>Domm</surname><given-names>S</given-names></name><name><surname>Gollnick</surname><given-names>H</given-names></name><etal/></person-group><article-title>Therapy of psoriasis in childhood and adolescence&#x02014;a German expert consensus</article-title><source>J Ger Soc Dermatol</source><year>2011</year><volume>9</volume><issue>10</issue><fpage>815</fpage><lpage>823</lpage></element-citation></ref><ref id="CR62"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bhutani</surname><given-names>T</given-names></name><name><surname>Kamangar</surname><given-names>F</given-names></name><name><surname>Cordoro</surname><given-names>KM</given-names></name></person-group><article-title>Management of pediatric psoriasis</article-title><source>Pediatr Ann</source><year>2012</year><volume>41</volume><issue>1</issue><fpage>e1</fpage><lpage>e7</lpage><pub-id pub-id-type="pmid">22224488</pub-id></element-citation></ref><ref id="CR63"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Jager</surname><given-names>ME</given-names></name><name><surname>de Jong</surname><given-names>EM</given-names></name><name><surname>van de Kerkhof</surname><given-names>PC</given-names></name><name><surname>Seyger</surname><given-names>MM</given-names></name></person-group><article-title>Efficacy and safety of treatments for childhood psoriasis: a systematic literature review</article-title><source>J Am Acad Dermatol</source><year>2010</year><volume>62</volume><issue>6</issue><fpage>1013</fpage><lpage>1030</lpage><pub-id pub-id-type="pmid">19900732</pub-id></element-citation></ref><ref id="CR64"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kimball</surname><given-names>AB</given-names></name><name><surname>Gold</surname><given-names>MH</given-names></name><name><surname>Zib</surname><given-names>B</given-names></name><name><surname>Davis</surname><given-names>MW</given-names></name><collab>Clobetasol Propionate Emulsion Formulation Foam Phase IIICSG</collab></person-group><article-title>Clobetasol propionate emulsion formulation foam 0.05&#x000a0;%: review of phase II open-label and phase III randomized controlled trials in steroid-responsive dermatoses in adults and adolescents</article-title><source>J Am Acad Dermatol</source><year>2008</year><volume>59</volume><issue>3</issue><fpage>448</fpage><lpage>454</lpage><pub-id pub-id-type="pmid">18539358</pub-id></element-citation></ref><ref id="CR65"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Herz</surname><given-names>G</given-names></name><name><surname>Blum</surname><given-names>G</given-names></name><name><surname>Yawalkar</surname><given-names>S</given-names></name></person-group><article-title>Halobetasol propionate cream by day and halobetasol propionate ointment at night for the treatment of pediatric patients with chronic, localized plaque psoriasis and atopic dermatitis</article-title><source>J Am Acad Dermatol</source><year>1991</year><volume>25</volume><issue>6 Pt 2</issue><fpage>1166</fpage><lpage>1169</lpage><pub-id pub-id-type="pmid">1757611</pub-id></element-citation></ref><ref id="CR66"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Darley</surname><given-names>CR</given-names></name><name><surname>Cunliffe</surname><given-names>WJ</given-names></name><name><surname>Green</surname><given-names>CM</given-names></name><name><surname>Hutchinson</surname><given-names>PE</given-names></name><name><surname>Klaber</surname><given-names>MR</given-names></name><name><surname>Downes</surname><given-names>N</given-names></name></person-group><article-title>Safety and efficacy of calcipotriol ointment (Dovonex) in treating children with psoriasis vulgaris</article-title><source>Br J Dermatol</source><year>1996</year><volume>135</volume><issue>3</issue><fpage>390</fpage><lpage>393</lpage><pub-id pub-id-type="pmid">8949431</pub-id></element-citation></ref><ref id="CR67"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oranje</surname><given-names>AP</given-names></name><name><surname>Marcoux</surname><given-names>D</given-names></name><name><surname>Svensson</surname><given-names>A</given-names></name><name><surname>Prendiville</surname><given-names>J</given-names></name><name><surname>Krafchik</surname><given-names>B</given-names></name><name><surname>Toole</surname><given-names>J</given-names></name><etal/></person-group><article-title>Topical calcipotriol in childhood psoriasis</article-title><source>J Am Acad Dermatol</source><year>1997</year><volume>36</volume><issue>2 Pt 1</issue><fpage>203</fpage><lpage>208</lpage><pub-id pub-id-type="pmid">9039169</pub-id></element-citation></ref><ref id="CR68"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van de Kerkhof</surname><given-names>PC</given-names></name><name><surname>Hoffmann</surname><given-names>V</given-names></name><name><surname>Anstey</surname><given-names>A</given-names></name><name><surname>Barnes</surname><given-names>L</given-names></name><name><surname>Bolduc</surname><given-names>C</given-names></name><name><surname>Reich</surname><given-names>K</given-names></name><etal/></person-group><article-title>A new scalp formulation of calcipotriol plus betamethasone dipropionate compared with each of its active ingredients in the same vehicle for the treatment of scalp psoriasis: a randomized, double-blind, controlled trial</article-title><source>Br J Dermatol</source><year>2009</year><volume>160</volume><issue>1</issue><fpage>170</fpage><lpage>176</lpage><pub-id pub-id-type="pmid">19067709</pub-id></element-citation></ref><ref id="CR69"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Geel</surname><given-names>MJ</given-names></name><name><surname>Mul</surname><given-names>K</given-names></name><name><surname>Oostveen</surname><given-names>AM</given-names></name><name><surname>van de Kerkhof</surname><given-names>PC</given-names></name><name><surname>de Jong</surname><given-names>EM</given-names></name><name><surname>Seyger</surname><given-names>MM</given-names></name></person-group><article-title>Calcipotriol/betamethasone dipropionate ointment in mild-to-moderate paediatric psoriasis: long-term daily clinical practice data in a prospective cohort</article-title><source>Br J Dermatol</source><year>2014</year><volume>171</volume><issue>2</issue><fpage>363</fpage><lpage>369</lpage><pub-id pub-id-type="pmid">24593129</pub-id></element-citation></ref><ref id="CR70"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gooderham</surname><given-names>M</given-names></name><name><surname>Debarre</surname><given-names>JM</given-names></name><name><surname>Keddy-Grant</surname><given-names>J</given-names></name><name><surname>Xu</surname><given-names>Z</given-names></name><name><surname>Kurvits</surname><given-names>M</given-names></name><name><surname>Goodfield</surname><given-names>M</given-names></name></person-group><article-title>Safety and efficacy of calcipotriol plus betamethasone dipropionate gel in the treatment of scalp psoriasis in adolescents 12&#x02013;17 years of age</article-title><source>Br J Dermatol</source><year>2014</year><volume>171</volume><issue>6</issue><fpage>1470</fpage><lpage>1477</lpage><pub-id pub-id-type="pmid">24980277</pub-id></element-citation></ref><ref id="CR71"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oostveen</surname><given-names>AM</given-names></name><name><surname>de Jong</surname><given-names>EM</given-names></name><name><surname>Donders</surname><given-names>AR</given-names></name><name><surname>van de Kerkhof</surname><given-names>PC</given-names></name><name><surname>Seyger</surname><given-names>MM</given-names></name></person-group><article-title>Treatment of paediatric scalp psoriasis with calcipotriene/betamethasone dipropionate scalp formulation: effectiveness, safety and influence on children&#x02019;s quality of life in daily practice</article-title><source>J Eur Acad Dermatol Venereol: JEADV</source><year>2015</year><volume>29</volume><issue>6</issue><fpage>1193</fpage><lpage>1197</lpage><pub-id pub-id-type="pmid">25307472</pub-id></element-citation></ref><ref id="CR72"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>C</given-names></name><name><surname>Lin</surname><given-names>A</given-names></name></person-group><article-title>Efficacy of topical calcineurin inhibitors in psoriasis</article-title><source>J Cutan Med Surg</source><year>2014</year><volume>18</volume><issue>1</issue><fpage>8</fpage><lpage>14</lpage><pub-id pub-id-type="pmid">24377467</pub-id></element-citation></ref><ref id="CR73"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Steele</surname><given-names>JA</given-names></name><name><surname>Choi</surname><given-names>C</given-names></name><name><surname>Kwong</surname><given-names>PC</given-names></name></person-group><article-title>Topical tacrolimus in the treatment of inverse psoriasis in children</article-title><source>J Am Acad Dermatol</source><year>2005</year><volume>53</volume><issue>4</issue><fpage>713</fpage><lpage>716</lpage><pub-id pub-id-type="pmid">16198804</pub-id></element-citation></ref><ref id="CR74"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brune</surname><given-names>A</given-names></name><name><surname>Miller</surname><given-names>DW</given-names></name><name><surname>Lin</surname><given-names>P</given-names></name><name><surname>Cotrim-Russi</surname><given-names>D</given-names></name><name><surname>Paller</surname><given-names>AS</given-names></name></person-group><article-title>Tacrolimus ointment is effective for psoriasis on the face and intertriginous areas in pediatric patients</article-title><source>Pediatr Dermatol</source><year>2007</year><volume>24</volume><issue>1</issue><fpage>76</fpage><lpage>80</lpage><pub-id pub-id-type="pmid">17300658</pub-id></element-citation></ref><ref id="CR75"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Jager</surname><given-names>ME</given-names></name><name><surname>van de Kerkhof</surname><given-names>PC</given-names></name><name><surname>de Jong</surname><given-names>EM</given-names></name><name><surname>Seyger</surname><given-names>MM</given-names></name></person-group><article-title>Dithranol therapy in childhood psoriasis: unjustifiably on the verge of falling into oblivion</article-title><source>Dermatology</source><year>2010</year><volume>220</volume><issue>4</issue><fpage>329</fpage><lpage>332</lpage><pub-id pub-id-type="pmid">20389024</pub-id></element-citation></ref><ref id="CR76"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oostveen</surname><given-names>AM</given-names></name><name><surname>Beulens</surname><given-names>CA</given-names></name><name><surname>van de Kerkhof</surname><given-names>PC</given-names></name><name><surname>de Jong</surname><given-names>EM</given-names></name><name><surname>Seyger</surname><given-names>MM</given-names></name></person-group><article-title>The effectiveness and safety of short-contact dithranol therapy in paediatric psoriasis: a prospective comparison of regular day care and day care with telemedicine</article-title><source>Br J Dermatol</source><year>2014</year><volume>170</volume><issue>2</issue><fpage>454</fpage><lpage>457</lpage><pub-id pub-id-type="pmid">24024678</pub-id></element-citation></ref><ref id="CR77"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zamberk</surname><given-names>P</given-names></name><name><surname>Velazquez</surname><given-names>D</given-names></name><name><surname>Campos</surname><given-names>M</given-names></name><name><surname>Hernanz</surname><given-names>JM</given-names></name><name><surname>Lazaro</surname><given-names>P</given-names></name></person-group><article-title>Paediatric psoriasis&#x02014;narrowband UVB treatment</article-title><source>J Eur Acad Dermatol Venereol: JEADV</source><year>2010</year><volume>24</volume><issue>4</issue><fpage>415</fpage><lpage>419</lpage><pub-id pub-id-type="pmid">19754659</pub-id></element-citation></ref><ref id="CR78"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pavlovsky</surname><given-names>M</given-names></name><name><surname>Baum</surname><given-names>S</given-names></name><name><surname>Shpiro</surname><given-names>D</given-names></name><name><surname>Pavlovsky</surname><given-names>L</given-names></name><name><surname>Pavlotsky</surname><given-names>F</given-names></name></person-group><article-title>Narrow band UVB: is it effective and safe for paediatric psoriasis and atopic dermatitis?</article-title><source>J Eur Acad Dermatol Venereol: JEADV</source><year>2011</year><volume>25</volume><issue>6</issue><fpage>727</fpage><lpage>729</lpage><pub-id pub-id-type="pmid">20726938</pub-id></element-citation></ref><ref id="CR79"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lara-Corrales</surname><given-names>I</given-names></name><name><surname>Ramnarine</surname><given-names>S</given-names></name><name><surname>Lansang</surname><given-names>P</given-names></name></person-group><article-title>Treatment of childhood psoriasis with phototherapy and photochemotherapy</article-title><source>Clin Med Insights Pediatr</source><year>2013</year><volume>7</volume><fpage>25</fpage><lpage>33</lpage><pub-id pub-id-type="pmid">23966809</pub-id></element-citation></ref><ref id="CR80"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jury</surname><given-names>CS</given-names></name><name><surname>McHenry</surname><given-names>P</given-names></name><name><surname>Burden</surname><given-names>AD</given-names></name><name><surname>Lever</surname><given-names>R</given-names></name><name><surname>Bilsland</surname><given-names>D</given-names></name></person-group><article-title>Narrowband ultraviolet B (UVB) phototherapy in children</article-title><source>Clin Exp Dermatol</source><year>2006</year><volume>31</volume><issue>2</issue><fpage>196</fpage><lpage>199</lpage><pub-id pub-id-type="pmid">16487089</pub-id></element-citation></ref><ref id="CR81"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Patel</surname><given-names>RV</given-names></name><name><surname>Clark</surname><given-names>LN</given-names></name><name><surname>Lebwohl</surname><given-names>M</given-names></name><name><surname>Weinberg</surname><given-names>JM</given-names></name></person-group><article-title>Treatments for psoriasis and the risk of malignancy</article-title><source>J Am Acad Dermatol</source><year>2009</year><volume>60</volume><issue>6</issue><fpage>1001</fpage><lpage>1017</lpage><pub-id pub-id-type="pmid">19344980</pub-id></element-citation></ref><ref id="CR82"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Archier</surname><given-names>E</given-names></name><name><surname>Devaux</surname><given-names>S</given-names></name><name><surname>Castela</surname><given-names>E</given-names></name><name><surname>Gallini</surname><given-names>A</given-names></name><name><surname>Aubin</surname><given-names>F</given-names></name><name><surname>Le Maitre</surname><given-names>M</given-names></name><etal/></person-group><article-title>Carcinogenic risks of psoralen UV-A therapy and narrowband UV-B therapy in chronic plaque psoriasis: a systematic literature review</article-title><source>J Eur Acad Dermatol Venereol: JEADV</source><year>2012</year><volume>26</volume><issue>Suppl 3</issue><fpage>22</fpage><lpage>31</lpage><pub-id pub-id-type="pmid">22512677</pub-id></element-citation></ref><ref id="CR83"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Yang</surname><given-names>M</given-names></name><name><surname>Cheng</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>GJ</given-names></name><name><surname>Zhang</surname><given-names>M</given-names></name></person-group><article-title>Narrow-band ultraviolet B phototherapy versus broad-band ultraviolet B or psoralen-ultraviolet A photochemotherapy for psoriasis</article-title><source>Cochrane Database Syst Rev</source><year>2013</year><volume>10</volume><fpage>CD009481</fpage><pub-id pub-id-type="pmid">24151011</pub-id></element-citation></ref><ref id="CR84"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zweegers</surname><given-names>J</given-names></name><name><surname>de Jong</surname><given-names>EM</given-names></name><name><surname>Nijsten</surname><given-names>TE</given-names></name><name><surname>de Bes</surname><given-names>J</given-names></name><name><surname>te Booij</surname><given-names>M</given-names></name><name><surname>Bogonjen</surname><given-names>RJ</given-names></name><etal/></person-group><article-title>Summary of the Dutch S3-guidelines on the treatment of psoriasis 2011</article-title><source>Dermatol Online J</source><year>2014</year><volume>20</volume><issue>3</issue><fpage>1</fpage><lpage>112</lpage></element-citation></ref><ref id="CR85"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Geel</surname><given-names>MJ</given-names></name><name><surname>Mul</surname><given-names>K</given-names></name><name><surname>de Jager</surname><given-names>ME</given-names></name><name><surname>van de Kerkhof</surname><given-names>PC</given-names></name><name><surname>de Jong</surname><given-names>EM</given-names></name><name><surname>Seyger</surname><given-names>MM</given-names></name></person-group><article-title>Systemic treatments in paediatric psoriasis: a systematic evidence-based update</article-title><source>J Eur Acad Dermatol Venereol: JEADV</source><year>2015</year><volume>29</volume><issue>3</issue><fpage>425</fpage><lpage>437</lpage><pub-id pub-id-type="pmid">25346019</pub-id></element-citation></ref><ref id="CR86"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wright</surname><given-names>NA</given-names></name><name><surname>Piggott</surname><given-names>CD</given-names></name><name><surname>Eichenfield</surname><given-names>LF</given-names></name></person-group><article-title>The role of biologics and other systemic agents in the treatment of pediatric psoriasis</article-title><source>Semin Cutan Med Surg</source><year>2010</year><volume>29</volume><issue>1</issue><fpage>20</fpage><lpage>27</lpage><pub-id pub-id-type="pmid">20430304</pub-id></element-citation></ref><ref id="CR87"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Geel</surname><given-names>MJ</given-names></name><name><surname>Oostveen</surname><given-names>AM</given-names></name><name><surname>Hoppenreijs</surname><given-names>EP</given-names></name><name><surname>Hendriks</surname><given-names>JC</given-names></name><name><surname>Kerkhof</surname><given-names>PC</given-names></name><name><surname>de Jong</surname><given-names>EM</given-names></name><etal/></person-group><article-title>Methotrexate in pediatric plaque-type psoriasis: long-term daily clinical practice results from the Child-CAPTURE registry</article-title><source>J Dermatol Treat</source><year>2015</year><volume>20</volume><fpage>1</fpage><lpage>7</lpage></element-citation></ref><ref id="CR88"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Posso-De Los Rios</surname><given-names>CJ</given-names></name><name><surname>Pope</surname><given-names>E</given-names></name><name><surname>Lara-Corrales</surname><given-names>I</given-names></name></person-group><article-title>A systematic review of systemic medications for pustular psoriasis in pediatrics</article-title><source>Pediatr Dermatol</source><year>2014</year><volume>31</volume><issue>4</issue><fpage>430</fpage><lpage>439</lpage><pub-id pub-id-type="pmid">24890463</pub-id></element-citation></ref><ref id="CR89"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marqueling</surname><given-names>AL</given-names></name><name><surname>Cordoro</surname><given-names>KM</given-names></name></person-group><article-title>Systemic treatments for severe pediatric psoriasis: a practical approach</article-title><source>Dermatol Clin</source><year>2013</year><volume>31</volume><issue>2</issue><fpage>267</fpage><lpage>288</lpage><pub-id pub-id-type="pmid">23557655</pub-id></element-citation></ref><ref id="CR90"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pathirana</surname><given-names>D</given-names></name><name><surname>Ormerod</surname><given-names>AD</given-names></name><name><surname>Saiag</surname><given-names>P</given-names></name><name><surname>Smith</surname><given-names>C</given-names></name><name><surname>Spuls</surname><given-names>PI</given-names></name><name><surname>Nast</surname><given-names>A</given-names></name><etal/></person-group><article-title>European S3-guidelines on the systemic treatment of psoriasis vulgaris</article-title><source>J Eur Acad Dermatol Venereol: JEADV</source><year>2009</year><volume>23</volume><issue>Suppl 2</issue><fpage>1</fpage><lpage>70</lpage><pub-id pub-id-type="pmid">19712190</pub-id></element-citation></ref><ref id="CR91"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaur</surname><given-names>I</given-names></name><name><surname>Dogra</surname><given-names>S</given-names></name><name><surname>De</surname><given-names>D</given-names></name><name><surname>Kanwar</surname><given-names>AJ</given-names></name></person-group><article-title>Systemic methotrexate treatment in childhood psoriasis: further experience in 24 children from India</article-title><source>Pediatr Dermatol</source><year>2008</year><volume>25</volume><issue>2</issue><fpage>184</fpage><lpage>188</lpage><pub-id pub-id-type="pmid">18429775</pub-id></element-citation></ref><ref id="CR92"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hashkes</surname><given-names>PJ</given-names></name><name><surname>Becker</surname><given-names>ML</given-names></name><name><surname>Cabral</surname><given-names>DA</given-names></name><name><surname>Laxer</surname><given-names>RM</given-names></name><name><surname>Paller</surname><given-names>AS</given-names></name><name><surname>Rabinovich</surname><given-names>CE</given-names></name><etal/></person-group><article-title>Methotrexate: new uses for an old drug</article-title><source>J Pediatr</source><year>2014</year><volume>164</volume><issue>2</issue><fpage>231</fpage><lpage>236</lpage><pub-id pub-id-type="pmid">24286573</pub-id></element-citation></ref><ref id="CR93"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kilic</surname><given-names>SS</given-names></name><name><surname>Hacimustafaoglu</surname><given-names>M</given-names></name><name><surname>Celebi</surname><given-names>S</given-names></name><name><surname>Karadeniz</surname><given-names>A</given-names></name><name><surname>Ildirim</surname><given-names>I</given-names></name></person-group><article-title>Low dose cyclosporin A treatment in generalized pustular psoriasis</article-title><source>Pediatr Dermatol</source><year>2001</year><volume>18</volume><issue>3</issue><fpage>246</fpage><lpage>248</lpage><pub-id pub-id-type="pmid">11438009</pub-id></element-citation></ref><ref id="CR94"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mahe</surname><given-names>E</given-names></name><name><surname>Bodemer</surname><given-names>C</given-names></name><name><surname>Pruszkowski</surname><given-names>A</given-names></name><name><surname>Teillac-Hamel</surname><given-names>D</given-names></name><name><surname>de Prost</surname><given-names>Y</given-names></name></person-group><article-title>Cyclosporine in childhood psoriasis</article-title><source>Arch Dermatol</source><year>2001</year><volume>137</volume><issue>11</issue><fpage>1532</fpage><lpage>1533</lpage><pub-id pub-id-type="pmid">11708969</pub-id></element-citation></ref><ref id="CR95"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alli</surname><given-names>N</given-names></name><name><surname>Gungor</surname><given-names>E</given-names></name><name><surname>Karakayali</surname><given-names>G</given-names></name><name><surname>Lenk</surname><given-names>N</given-names></name><name><surname>Artuz</surname><given-names>F</given-names></name></person-group><article-title>The use of cyclosporin in a child with generalized pustular psoriasis</article-title><source>Br J Dermatol</source><year>1998</year><volume>139</volume><issue>4</issue><fpage>754</fpage><lpage>755</lpage><pub-id pub-id-type="pmid">9892934</pub-id></element-citation></ref><ref id="CR96"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>HS</given-names></name><name><surname>Kim</surname><given-names>GM</given-names></name><name><surname>Kim</surname><given-names>SY</given-names></name></person-group><article-title>Two-stage therapy for childhood generalized pustular psoriasis: low-dose cyclosporin for induction and maintenance with acitretin/narrowband ultraviolet B phototherapy</article-title><source>Pediatr Dermatol</source><year>2006</year><volume>23</volume><issue>3</issue><fpage>306</fpage><lpage>308</lpage><pub-id pub-id-type="pmid">16780493</pub-id></element-citation></ref><ref id="CR97"><label>97.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chao</surname><given-names>PH</given-names></name><name><surname>Cheng</surname><given-names>YW</given-names></name><name><surname>Chung</surname><given-names>MY</given-names></name></person-group><article-title>Generalized pustular psoriasis in a 6-week-old infant</article-title><source>Pediatr Dermatol</source><year>2009</year><volume>26</volume><issue>3</issue><fpage>352</fpage><lpage>354</lpage><pub-id pub-id-type="pmid">19706107</pub-id></element-citation></ref><ref id="CR98"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sarkar</surname><given-names>S</given-names></name><name><surname>Das</surname><given-names>K</given-names></name><name><surname>Roychoudhury</surname><given-names>S</given-names></name><name><surname>Shrimal</surname><given-names>A</given-names></name></person-group><article-title>Pseudotumor cerebri in a child treated with acitretin: a rare occurrence</article-title><source>Indian J Pharmacol</source><year>2013</year><volume>45</volume><issue>1</issue><fpage>89</fpage><lpage>90</lpage><pub-id pub-id-type="pmid">23543097</pub-id></element-citation></ref><ref id="CR99"><label>99.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cordoro</surname><given-names>KM</given-names></name></person-group><article-title>Management of childhood psoriasis</article-title><source>Adv Dermatol</source><year>2008</year><volume>24</volume><fpage>125</fpage><lpage>169</lpage><pub-id pub-id-type="pmid">19256308</pub-id></element-citation></ref><ref id="CR100"><label>100.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Balak</surname><given-names>DM</given-names></name><name><surname>Oostveen</surname><given-names>AM</given-names></name><name><surname>Bousema</surname><given-names>MT</given-names></name><name><surname>Venema</surname><given-names>AW</given-names></name><name><surname>Arnold</surname><given-names>WP</given-names></name><name><surname>Seyger</surname><given-names>MM</given-names></name><etal/></person-group><article-title>Effectiveness and safety of fumaric acid esters in children with psoriasis: a retrospective analysis of 14 patients from The Netherlands</article-title><source>Br J Dermatol</source><year>2013</year><volume>168</volume><issue>6</issue><fpage>1343</fpage><lpage>1347</lpage><pub-id pub-id-type="pmid">23738641</pub-id></element-citation></ref><ref id="CR101"><label>101.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoefnagel</surname><given-names>JJ</given-names></name><name><surname>Thio</surname><given-names>HB</given-names></name><name><surname>Willemze</surname><given-names>R</given-names></name></person-group><article-title>Bouwes Bavinck JN. Long-term safety aspects of systemic therapy with fumaric acid esters in severe psoriasis</article-title><source>Br J Dermatol</source><year>2003</year><volume>149</volume><issue>2</issue><fpage>363</fpage><lpage>369</lpage><pub-id pub-id-type="pmid">12932244</pub-id></element-citation></ref><ref id="CR102"><label>102.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gerdes</surname><given-names>S</given-names></name><name><surname>Domm</surname><given-names>S</given-names></name><name><surname>Mrowietz</surname><given-names>U</given-names></name></person-group><article-title>Long-term treatment with fumaric acid esters in an 11-year-old male child with psoriasis</article-title><source>Dermatology</source><year>2011</year><volume>222</volume><issue>3</issue><fpage>198</fpage><lpage>200</lpage><pub-id pub-id-type="pmid">21502753</pub-id></element-citation></ref><ref id="CR103"><label>103.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Steeman</surname><given-names>AS</given-names></name><name><surname>Balak</surname><given-names>DM</given-names></name><name><surname>Seijger</surname><given-names>MMB</given-names></name><name><surname>Thio</surname><given-names>HB</given-names></name><name><surname>Bousema</surname><given-names>MT</given-names></name></person-group><article-title>Fumaraten bij een meisje van vijftien jaar met psoriasis!</article-title><source>Nederlands Tijdschrift voor Dermatologie &#x00026; Venereologie</source><year>2012</year><volume>22</volume><issue>5</issue><fpage>308</fpage><lpage>311</lpage></element-citation></ref><ref id="CR104"><label>104.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gunther</surname><given-names>CH</given-names></name></person-group><article-title>Successive use of fumaric acid esters for the treatment of psoriasis vulgaris in a 14-year-old patient [German]</article-title><source>Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete</source><year>2004</year><volume>15</volume><issue>1</issue><fpage>28</fpage><lpage>30</lpage></element-citation></ref><ref id="CR105"><label>105.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paller</surname><given-names>AS</given-names></name><name><surname>Siegfried</surname><given-names>EC</given-names></name><name><surname>Langley</surname><given-names>RG</given-names></name><name><surname>Gottlieb</surname><given-names>AB</given-names></name><name><surname>Pariser</surname><given-names>D</given-names></name><name><surname>Landells</surname><given-names>I</given-names></name><etal/></person-group><article-title>Etanercept treatment for children and adolescents with plaque psoriasis</article-title><source>N Engl J Med</source><year>2008</year><volume>358</volume><issue>3</issue><fpage>241</fpage><lpage>251</lpage><pub-id pub-id-type="pmid">18199863</pub-id></element-citation></ref><ref id="CR106"><label>106.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luu</surname><given-names>M</given-names></name><name><surname>Cordoro</surname><given-names>KM</given-names></name></person-group><article-title>The evolving role of biologics in the treatment of pediatric psoriasis</article-title><source>Skin Therapy Lett</source><year>2013</year><volume>18</volume><issue>2</issue><fpage>1</fpage><lpage>4</lpage><pub-id pub-id-type="pmid">23508772</pub-id></element-citation></ref><ref id="CR107"><label>107.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sukhatme</surname><given-names>SV</given-names></name><name><surname>Gottlieb</surname><given-names>AB</given-names></name></person-group><article-title>Pediatric psoriasis: updates in biologic therapies</article-title><source>Dermatol Therapy</source><year>2009</year><volume>22</volume><issue>1</issue><fpage>34</fpage><lpage>39</lpage></element-citation></ref><ref id="CR108"><label>108.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paller</surname><given-names>AS</given-names></name><name><surname>Siegfried</surname><given-names>EC</given-names></name><name><surname>Eichenfield</surname><given-names>LF</given-names></name><name><surname>Pariser</surname><given-names>D</given-names></name><name><surname>Langley</surname><given-names>RG</given-names></name><name><surname>Creamer</surname><given-names>K</given-names></name><etal/></person-group><article-title>Long-term etanercept in pediatric patients with plaque psoriasis</article-title><source>J Am Acad Dermatol</source><year>2010</year><volume>63</volume><issue>5</issue><fpage>762</fpage><lpage>768</lpage><pub-id pub-id-type="pmid">20605256</pub-id></element-citation></ref><ref id="CR109"><label>109.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lovell</surname><given-names>DJ</given-names></name><name><surname>Reiff</surname><given-names>A</given-names></name><name><surname>Ilowite</surname><given-names>NT</given-names></name><name><surname>Wallace</surname><given-names>CA</given-names></name><name><surname>Chon</surname><given-names>Y</given-names></name><name><surname>Lin</surname><given-names>SL</given-names></name><etal/></person-group><article-title>Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis</article-title><source>Arthritis Rheum</source><year>2008</year><volume>58</volume><issue>5</issue><fpage>1496</fpage><lpage>1504</lpage><pub-id pub-id-type="pmid">18438876</pub-id></element-citation></ref><ref id="CR110"><label>110.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prince</surname><given-names>FH</given-names></name><name><surname>Twilt</surname><given-names>M</given-names></name><name><surname>ten Cate</surname><given-names>R</given-names></name><name><surname>van Rossum</surname><given-names>MA</given-names></name><name><surname>Armbrust</surname><given-names>W</given-names></name><name><surname>Hoppenreijs</surname><given-names>EP</given-names></name><etal/></person-group><article-title>Long-term follow-up on effectiveness and safety of etanercept in juvenile idiopathic arthritis: the Dutch national register</article-title><source>Ann Rheum Dis</source><year>2009</year><volume>68</volume><issue>5</issue><fpage>635</fpage><lpage>641</lpage><pub-id pub-id-type="pmid">18413443</pub-id></element-citation></ref><ref id="CR111"><label>111.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bellodi Schmidt</surname><given-names>F</given-names></name><name><surname>Shah</surname><given-names>KN</given-names></name></person-group><article-title>Biologic response modifiers and pediatric psoriasis</article-title><source>Pediatr Dermatol</source><year>2015</year><volume>32</volume><issue>3</issue><fpage>303</fpage><lpage>320</lpage><pub-id pub-id-type="pmid">25727936</pub-id></element-citation></ref><ref id="CR112"><label>112.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dini</surname><given-names>V</given-names></name><name><surname>Barbanera</surname><given-names>S</given-names></name><name><surname>Romanelli</surname><given-names>M</given-names></name></person-group><article-title>Efficacy of adalimumab for the treatment of refractory paediatric acrodermatitis continua of hallopeau</article-title><source>Acta Dermato-Venereologica</source><year>2013</year><volume>93</volume><issue>5</issue><fpage>588</fpage><lpage>589</lpage><pub-id pub-id-type="pmid">23407925</pub-id></element-citation></ref><ref id="CR113"><label>113.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moretti</surname><given-names>D</given-names></name><name><surname>Cianchi</surname><given-names>I</given-names></name><name><surname>Vannucci</surname><given-names>G</given-names></name><name><surname>Cimaz</surname><given-names>R</given-names></name><name><surname>Simonini</surname><given-names>G</given-names></name></person-group><article-title>Psoriatic juvenile idiopathic arthritis associated with uveitis: a case report</article-title><source>Case Rep Rheumatol</source><year>2013</year><volume>2013</volume><fpage>595890</fpage><pub-id pub-id-type="pmid">24191219</pub-id></element-citation></ref><ref id="CR114"><label>114.</label><mixed-citation publication-type="other">A double blind study in pediatric subjects with chronic plaque psoriasis, studying adalimumab vs methotrexate [online]. <ext-link ext-link-type="uri" xlink:href="https://www.clinicaltrials.gov/ct2/show/NCT01251614">https://www.clinicaltrials.gov/ct2/show/NCT01251614</ext-link>. NLM identifier: NCT01251614. Accessed 4 May 2015.</mixed-citation></ref><ref id="CR115"><label>115.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fotiadou</surname><given-names>C</given-names></name><name><surname>Lazaridou</surname><given-names>E</given-names></name><name><surname>Giannopoulou</surname><given-names>C</given-names></name><name><surname>Ioannides</surname><given-names>D</given-names></name></person-group><article-title>Ustekinumab for the treatment of an adolescent patient with recalcitrant plaque psoriasis</article-title><source>Eur J Dermatol: EJD.</source><year>2011</year><volume>21</volume><issue>1</issue><fpage>117</fpage><lpage>118</lpage><pub-id pub-id-type="pmid">21233068</pub-id></element-citation></ref><ref id="CR116"><label>116.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dixit</surname><given-names>S</given-names></name><name><surname>Shumack</surname><given-names>S</given-names></name><name><surname>Fischer</surname><given-names>G</given-names></name></person-group><article-title>Ustekinumab in the treatment of severe paediatric psoriasis</article-title><source>Aust J Dermatol</source><year>2013</year><volume>54</volume><issue>2</issue><fpage>147</fpage></element-citation></ref><ref id="CR117"><label>117.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>AbuHilal</surname><given-names>M</given-names></name><name><surname>Ho</surname><given-names>N</given-names></name></person-group><article-title>Successful treatment of severe psoriasis in an adolescent with ustekinumab</article-title><source>Pediatr Dermatol</source><year>2015</year><volume>32</volume><issue>3</issue><fpage>377</fpage><lpage>380</lpage><pub-id pub-id-type="pmid">25727845</pub-id></element-citation></ref><ref id="CR118"><label>118.</label><mixed-citation publication-type="other">A study of the safety and efficacy of ustekinumab in adolescent patients with psoriasis (CADMUS) [online]. <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT01090427">https://clinicaltrials.gov/ct2/show/NCT01090427</ext-link>. NLM identifier: NCT01090427. Accessed 28 December 2014.</mixed-citation></ref><ref id="CR119"><label>119.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Augustin</surname><given-names>M</given-names></name><name><surname>Reich</surname><given-names>K</given-names></name><name><surname>Glaeske</surname><given-names>G</given-names></name><name><surname>Schaefer</surname><given-names>I</given-names></name><name><surname>Radtke</surname><given-names>M</given-names></name></person-group><article-title>Co-morbidity and age-related prevalence of psoriasis: analysis of health insurance data in Germany</article-title><source>Acta Dermato-Venereologica</source><year>2010</year><volume>90</volume><issue>2</issue><fpage>147</fpage><lpage>151</lpage><pub-id pub-id-type="pmid">20169297</pub-id></element-citation></ref><ref id="CR120"><label>120.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koebnick</surname><given-names>C</given-names></name><name><surname>Black</surname><given-names>MH</given-names></name><name><surname>Smith</surname><given-names>N</given-names></name><name><surname>Der-Sarkissian</surname><given-names>JK</given-names></name><name><surname>Porter</surname><given-names>AH</given-names></name><name><surname>Jacobsen</surname><given-names>SJ</given-names></name><etal/></person-group><article-title>The association of psoriasis and elevated blood lipids in overweight and obese children</article-title><source>J Pediatr</source><year>2011</year><volume>159</volume><issue>4</issue><fpage>577</fpage><lpage>583</lpage><pub-id pub-id-type="pmid">21524758</pub-id></element-citation></ref><ref id="CR121"><label>121.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Jager</surname><given-names>ME</given-names></name><name><surname>van de Kerkhof</surname><given-names>PC</given-names></name><name><surname>de Jong</surname><given-names>EM</given-names></name><name><surname>Seyger</surname><given-names>MM</given-names></name></person-group><article-title>A cross-sectional study using the Children&#x02019;s Dermatology Life Quality Index (CDLQI) in childhood psoriasis: negative effect on quality of life and moderate correlation of CDLQI with severity scores</article-title><source>Br J Dermatol</source><year>2010</year><volume>163</volume><issue>5</issue><fpage>1099</fpage><lpage>1101</lpage><pub-id pub-id-type="pmid">20716218</pub-id></element-citation></ref><ref id="CR122"><label>122.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mercy</surname><given-names>KM</given-names></name><name><surname>Paller</surname><given-names>AS</given-names></name></person-group><article-title>The relationship between obesity and psoriasis in the pediatric population: implications and future directions</article-title><source>Cutis</source><year>2013</year><volume>92</volume><issue>3</issue><fpage>107</fpage><lpage>109</lpage><pub-id pub-id-type="pmid">24153136</pub-id></element-citation></ref><ref id="CR123"><label>123.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jensen</surname><given-names>P</given-names></name><name><surname>Zachariae</surname><given-names>C</given-names></name><name><surname>Christensen</surname><given-names>R</given-names></name><name><surname>Geiker</surname><given-names>NR</given-names></name><name><surname>Schaadt</surname><given-names>BK</given-names></name><name><surname>Stender</surname><given-names>S</given-names></name><etal/></person-group><article-title>Effect of weight loss on the severity of psoriasis: a randomized clinical study</article-title><source>JAMA Dermatol</source><year>2013</year><volume>149</volume><issue>7</issue><fpage>795</fpage><lpage>801</lpage><pub-id pub-id-type="pmid">23752669</pub-id></element-citation></ref><ref id="CR124"><label>124.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Ferranti</surname><given-names>SD</given-names></name><name><surname>Gauvreau</surname><given-names>K</given-names></name><name><surname>Ludwig</surname><given-names>DS</given-names></name><name><surname>Neufeld</surname><given-names>EJ</given-names></name><name><surname>Newburger</surname><given-names>JW</given-names></name><name><surname>Rifai</surname><given-names>N</given-names></name></person-group><article-title>Prevalence of the metabolic syndrome in American adolescents: findings from the Third National Health and Nutrition Examination Survey</article-title><source>Circulation</source><year>2004</year><volume>110</volume><issue>16</issue><fpage>2494</fpage><lpage>2497</lpage><pub-id pub-id-type="pmid">15477412</pub-id></element-citation></ref><ref id="CR125"><label>125.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Au</surname><given-names>SC</given-names></name><name><surname>Goldminz</surname><given-names>AM</given-names></name><name><surname>Loo</surname><given-names>DS</given-names></name><name><surname>Dumont</surname><given-names>N</given-names></name><name><surname>Levine</surname><given-names>D</given-names></name><name><surname>Volf</surname><given-names>E</given-names></name><etal/></person-group><article-title>Association between pediatric psoriasis and the metabolic syndrome</article-title><source>J Am Acad Dermatol</source><year>2012</year><volume>66</volume><issue>6</issue><fpage>1012</fpage><lpage>1013</lpage><pub-id pub-id-type="pmid">22583717</pub-id></element-citation></ref><ref id="CR126"><label>126.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mahe</surname><given-names>E</given-names></name><name><surname>Maccari</surname><given-names>F</given-names></name><name><surname>Beauchet</surname><given-names>A</given-names></name><name><surname>Lahfa</surname><given-names>M</given-names></name><name><surname>Barthelemy</surname><given-names>H</given-names></name><name><surname>Reguiai</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Childhood-onset psoriasis: association with future cardiovascular and metabolic comorbidities</article-title><source>Br J Dermatol</source><year>2013</year><volume>169</volume><issue>4</issue><fpage>889</fpage><lpage>895</lpage><pub-id pub-id-type="pmid">23937622</pub-id></element-citation></ref><ref id="CR127"><label>127.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lewis-Jones</surname><given-names>MS</given-names></name><name><surname>Finlay</surname><given-names>AY</given-names></name></person-group><article-title>The Children&#x02019;s Dermatology Life Quality Index (CDLQI): initial validation and practical use</article-title><source>Br J Dermatol</source><year>1995</year><volume>132</volume><issue>6</issue><fpage>942</fpage><lpage>949</lpage><pub-id pub-id-type="pmid">7662573</pub-id></element-citation></ref><ref id="CR128"><label>128.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Langley</surname><given-names>RG</given-names></name><name><surname>Paller</surname><given-names>AS</given-names></name><name><surname>Hebert</surname><given-names>AA</given-names></name><name><surname>Creamer</surname><given-names>K</given-names></name><name><surname>Weng</surname><given-names>HH</given-names></name><name><surname>Jahreis</surname><given-names>A</given-names></name><etal/></person-group><article-title>Patient-reported outcomes in pediatric patients with psoriasis undergoing etanercept treatment: 12-week results from a phase III randomized controlled trial</article-title><source>J Am Acad Dermatol</source><year>2011</year><volume>64</volume><issue>1</issue><fpage>64</fpage><lpage>70</lpage><pub-id pub-id-type="pmid">20619489</pub-id></element-citation></ref><ref id="CR129"><label>129.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Akay</surname><given-names>A</given-names></name><name><surname>Pekcanlar</surname><given-names>A</given-names></name><name><surname>Bozdag</surname><given-names>KE</given-names></name><name><surname>Altintas</surname><given-names>L</given-names></name><name><surname>Karaman</surname><given-names>A</given-names></name></person-group><article-title>Assessment of depression in subjects with psoriasis vulgaris and lichen planus</article-title><source>J Eur Acad Dermatol Venereol: JEADV</source><year>2002</year><volume>16</volume><issue>4</issue><fpage>347</fpage><lpage>352</lpage><pub-id pub-id-type="pmid">12224690</pub-id></element-citation></ref><ref id="CR130"><label>130.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Russo</surname><given-names>PA</given-names></name><name><surname>Ilchef</surname><given-names>R</given-names></name><name><surname>Cooper</surname><given-names>AJ</given-names></name></person-group><article-title>Psychiatric morbidity in psoriasis: a review</article-title><source>Aust J Dermatol.</source><year>2004</year><volume>45</volume><issue>3</issue><fpage>155</fpage><lpage>159</lpage></element-citation></ref><ref id="CR131"><label>131.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Remrod</surname><given-names>C</given-names></name><name><surname>Sjostrom</surname><given-names>K</given-names></name><name><surname>Svensson</surname><given-names>A</given-names></name></person-group><article-title>Psychological differences between early- and late-onset psoriasis: a study of personality traits, anxiety and depression in psoriasis</article-title><source>Br J Dermatol</source><year>2013</year><volume>169</volume><issue>2</issue><fpage>344</fpage><lpage>350</lpage><pub-id pub-id-type="pmid">23565588</pub-id></element-citation></ref></ref-list></back></article>